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Abstract:  
TRIM41 is a member of TRIM family of host proteins. TRIM proteins are E3 ubiquitin ligase 
proteins and play important roles in various cellular functions like tumorigenesis, autophagy, 
innate, and intrinsic antiviral immunity. Structurally 3 domains of proteins are preserved 
throughout the family and the C-terminal domains are variable. TRIM41 is a protein that is 
ubiquitous and constitutively expressed in variety of cell types. N-terminal RING, B-BOX and 
Coiled Coil domains are conserved domains where as TRIM41 possesses a C- terminal SPRY 
domain.  Our proteomics studies of host-viral protein interaction network revealed interaction 
between TRIM41 and nucleoprotein of Influenza A virus (IAV).We found that TRIM41 interacts 
with nucleoprotein of these  Influenza A through its SPRY domain. Overexpression of 
TRIM41 in cells reduces the IAV infection whereas depletion of TRIM41 increases susceptibility 
of host cells to the infection. TRIM41 like all other TRIM proteins is a E3 ubiquitin ligase and it 
polyubiquitinates IAV nucleoprotein in-vitro and in cells. TRIM41 lacking E3 ligase activity fail 
to restrict viral infection indicating the importance of E3 ligase activity for TRIM41 in its 
antiviral function. During the study, TRIM41 was also identified as an inhibitor of vesicular 
stomatitis virus (VSV) infection. TRIM41 through its SPRY domain interacts with nucleoprotein 
of VSV. RING domain plays a crucial role in antiviral activity of TRIM41 against VSV. The 
interaction with TRIM41 leads to polyubiquitination and proteasomal degradation of  VSV 
nucleoprotein. Taken together, TRIM41 is a host intrinsic immune protein that functions against 
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Virus must engage with host cells to replicate and spread, which warrants profound changes in host 
cellular signaling pathways, especially the instigation of host immune responses. Host defenses are 
complex systemic immune responses at different levels, including intrinsic, innate and adaptive 
immunity. Recent studies show that the tripartite motif (TRIM) containing proteins play a versatile 
role in all layers of host immune defenses. TRIM proteins are a family of ubiquitin E3 ligases which 
share a characteristic N-terminal tripartite motif (also known as RBCC motif) consisting of a highly 
conserved order of three domains: the really interesting new gene (RING) domain, one or two B-box 
domains and a coiled coil region1. The RING domain confers TRIM proteins the ubiquitin E3 ligase 
activity 2. Ubiquitination is a translational modification which alters target protein stability, 
trafficking, subcellular localization, enzymatic activation and protein recruitment etc. TRIM proteins 
have been found to promote the host immune response by ubiquitination of critical signaling 
molecules in immunity and to interfere with viral infection by directly targeting viral proteins for 
degradation.  
 
TRIM proteins are also known to participate in other biological processes, such as development and 
carcinogenesis 
3
, however, TRIM proteins are gaining in importance in the field of viral immunity in 
recent years and the studies of TRIM proteins in host defense is one of the fastest growing subjects in 
the field of immunity. Thus, a systematic and comprehensive understanding of the role of TRIM 
proteins in multiple layers of host defense will not only help elucidate the antiviral mechanisms of 
TRIM proteins but also provide potential for developing new antiviral therapeutics. In this review, we 
focus on the role and the antiviral mechanisms of TRIM proteins in each layer of host immune 







TRIM PROTEIN:  STRUCTURE, CLASSIFICATION & EXPRESSION 
TRIM protein family consists of 76 members, which all share the RBCC motif. RBCC domain 
consists of three zinc binding motifs which are RING, B-box type 1 & 2 and coiled coil domain. The 
RING zinc finger motif is 40-60 amino acid long, which is essential for the ubiquitin E3 ligase 
activity and the binding with E2 conjugating enzyme 
4
. RING domain plays a crucial role in TRIM 
proteins-mediated ubiquitination 
5
. B-box domain presents in either single or paired form and plays a 
role in self-assembly of TRIM proteins and interaction with their substrates  
6
. Coiled coil is a 
common hyper-helical structure which involves protein-protein interaction, including protein 
dimerization
1,7
. Similarity, the coiled coil of TRIM mediates dimerization and self-association of 
TRIM proteins 
8,9
. Additionally, the coiled coil sequesters TRIM proteins in the cytoplasm or the 
nuclear bodies 
1
. The RBCC motif is followed by one or more domains located on the C-terminus of 
TRIM proteins. The TRIM superfamily is classified into 11 groups according to the C-terminal 
domains (Figure 1). Group 1 is featured with multiple domains, including the C-terminal subgroup 
one signature (COS), fibrinolectin type 3 (FN3) and SPRY domain. COS box domain is responsible 
for microtubule binding 
10
. FN3 binds heparin and DNA 
11
. The SPRY domain (also termed as B30.2) 






Figure 1. The schematics of the subgroups of TRIM proteins Each number in the column of 
TRIM family members is corresponding to the designated TRIM protein number. For example, 1 
stands for TRIM1. TRIM: Tripartite motif. 
Group 2 has a single COS domain whereas Group 3 has both COS and FN3 domains. Group 4 is the 
largest subfamily of TRIM proteins characterized by a SPRY domain at the C terminus. Group 5 has 
no defined motif in the C-terminal region. Group 6 has the PHD-BROMO domains while group 7 
possesses the NHL repeats. Bromodomains bind acetylated lysine residue on the N-terminal of 
histones and repress transcription 
13




are featured with MATH, ARF and filamin domain, respectively. Filament type immunoglobulin 
domains are responsible for dimerization and actin crosslinking whereas ADP ribosylation factor like 
(ARF) domains stimulates vesicular trafficking 
14,15
. MATH domain is important for receptor-TRAF 
protein interaction 
9
. Group 11 comprises a transmembrane domain in their C-terminal region. Taken 
together, the variable C-terminal domains of TRIM proteins contribute to the versatile binding ability 
to their substrate. 
TRIM proteins are found in many types of cells, such as immune cells. Interestingly, TRIM proteins 
are expressed differentially in B-cells, T-cells, dendritic cells, mast cells, NK-cells and macrophages  
8
, suggesting a regulatory mechanism for TRIM. In addition, TRIM proteins show different 
subcellular localizations. Many of them form cytoplasmic bodies when over-expressed 
16,17
. 
Mutations in the RING, coiled coil domain or B-box have been reported to cause aberrant localization 
11




TRIM PROTEINS AND UBIQUITINATION  
Ubiquitin is a highly conserved and ubiquitously expressed 76-amino acid protein. The ubiquitination 
process is a reversible covalent conjugation of ubiquitin to substrate by a three-stepwise enzymatic 
system (Fig. 2). In the first step, ubiquitin is activated by a ubiquitin-activating enzyme (E1) in an 
ATP-dependent reaction, in which the C-terminal carboxyl group of ubiquitin links to the sulfhydryl 
group of an E1 via a thioester bond. In the second step, the activated ubiquitin is transferred to a 
ubiquitin-conjugating enzyme (E2), forming an E2-Ub thioester. The E2 then acts with the ubiquitin 
ligase (E3) to conjugate ubiquitin to the substrate protein via an isopeptide bond between the C-
terminal glycine of ubiquitin and the lysine of substrate protein. To date, only two E1s (UBA1 and 
UBA6) and about 35 E2s have been identified in humans 
19,20
. Typically, a single E2 can interact with 
multiple E3s. Regarding to TRIM proteins, the Cys3-His-Cys4 zinc finger in the RING domain binds 
6 
 
several E2s, including UBE2D and UBE2E 
21
. Additionally, some TRIM proteins lack a RING 
domain, however, their B-box motifs comprise a zinc finger similar to the RING and confer the 




The ubiquitination process may be terminated after the attachment of a single ubiquitin moiety 
(mono-ubiquitination) or repeated either with additional ubiquitin molecules linked to the ubiquitin 
molecule previously attached to the substrate, forming a polyubiquitin chain. The C-terminus of 
ubiquitin can be conjugated to one of the seven lysines (K6, K11, K27, K29, K33, K48, K63) on 
another ubiquitin, forming polyubiquitin chain of different linkages. The linkage of polyubiquitin can 
influence the fate of the substrate, adding another layer of complexity to this modification. Majority 
of TRIM proteins mediate either K48- or K63-linked polyubiquitination of target proteins 
23,24
. The 
K48-linked ubiquitination is usually involved in directing proteins for proteasome-dependent 
degradation while the K63-linked ubiquitination involves non-proteolytic processes, such as 
subcellular localization, signalosome stability and activation, and trafficking etc. For example, 
TRIM32 targets influenza PB1 protein for K48-linked polyubiquitination, which results in PB1 
protein degradation and viral restriction
25
. In contrast, TRIM25 mediates K63-linked ubiquitination of 




Although most TRIM proteins are ubiquitin E3 ligases, several TRIM proteins also can act as a E3 
ligase for ubiquitin-like molecules, such as SUMO and ISG15. For instance, TRIM28 mediates 
sumoylation of IRF7, which leads to inhibition of IRF7 transactivation and IFN expression  
27
. It is 
also reported that TRIM25 is the ISG15 E3 ligase for 14-3-3 sigma protein, however, the biological 































Figure 2. The process of ubiquitination. Ubiquitin (Ub) is first activated by a ubiquitin-activating 
enzyme (E1) in an ATP-dependent reaction. The activated ubiquitin is then transferred to a ubiquitin-

































TRIM PROTEINS & INTRINSIC IMMUNITY 
Intrinsic immunity is the instant antiviral response by a group of constitutively expressed host factors 
through diverse mechanisms. The constitutive expression of these host factors guarantees the rapid 
and direct inhibition of viruses at almost every step of viral life cycle. A group of TRIM proteins 
belongs to these intrinsic factors which have been reported to curb viral infection through direct 
interaction with viral proteins. These TRIM proteins employ distinct mechanisms to inhibit viral 
entry, replication or dissemination. The intrinsic antiviral mechanism of each of these TRIM proteins 
will be discussed below (Fig. 3).  
 
Figure 3. The role of TRIM proteins in intrinsic immunity This figure illustrates that TRIM 
proteins employ distinct mechanisms to inhibit viral entry, replication or dissemination by interacting 





Table 1. Summary of the role of tripartite motif proteins in intrinsic immunity. 
TRIM protein Mode of action  
TRIM5α SPRY domain of TRIM5a interacts with the capsid of HIV and restricts the viral 
uncoating and replication. 
TRIM11 TRIM11 restricts HIV-1 reverse transcription by accelerating premature viral 
uncoating 
TRIM14 RINGIess TRIM14 interacts with HCV NS5A protein through SPRY domain and 
mediates its k48 polyubiquitination and degradation. 
TRIM19 TRIM19/PML blocks HIV viral replication at two distinct steps. First is at early 
postentry stage and it also causes silencing of transcription 
TRIM22 TRIM22 blocks the intracellular trafficking of the HIV viral structural protein Gag to 
the surface of the cell through its E3 ligase activity 
TRIM22 TRIM22 interacts with class II interactor and sp1, thus inhibits HIV viral gene 
transcription initiation and elongation 
TRIM22 TRIM22 targets influenza nucleoprotein and mediates its k48 polyubiquitination and 
degradation 
TRIM22 TRIM22 inhibits the activity of HBV core promoter by interacting through C-
terminal SPRY domain and acting as an E3 ligase. 
 
TRIM22 TRIM22 interacts with HCV NS5A protein through SPRY domain and mediates its 
k48 polyubiquitination and degradation 
TRIM22 TRIM22 interacts with the viral 3C protease (3C[PRO]) of encephalomyocarditis 
virus and mediates its ubiquitination and degradation 
TRIM25 TRIM25 inhibits viral RNA synthesis results from its binding to viral 
ribonucleoproteins (vRNPs) of influenza. 
TRIM28 TRIM28 binds to acetylated integrase and indeed deacetylation of it which restricts 
10 
 
integration of HIV viral cDNA into the host genome 
TRIM32 TRIM32 interacts with the PB1 of the influenza RNA polymerase complex and 
mediates its ubiquitination and proteasomal degradation 
TRIM52 TRIM52 act against Japanese encephalitis virus infection by targeting and degrading 
viral NS2A through ubiquitination 
TRIM56 TRIM56 inhibits BVDV replication by targeting an intracellular viral RNA 
replication 
TRIM56 TRIM56 restricts YFV and DENV2 through E3 ligase activity and C-terminal 
domain interaction 
TRIM56 TRIM56 specifically impede intracellular influenza virus RNA synthesis without 
acting as an E3 ligase. 
BVDV: bovine viral diarrhea virus; DENV: dengue virus; PML: Promyelocytic leukemia protein; 
TRIM: Tripartite motif; YFV: yellow fever virus. 
 
TRIM proteins-mediated intrinsic immunity to HIV-1 
TRIM5α is the prototype of TRIM proteins in intrinsic immunity. TRIM5α is a well-known cytosolic 
host restriction factor to the cross-species transmission of retroviruses, which protects the Old World 
monkeys including rhesus macaques from infection of HIV-1
29-32
 . The restriction specificity of 
TRIM5α is dependent on the its C-terminal PRY/SPRY domain which mediates the interaction with 
HIV-1 capsid 
33,34
. On the HIV-1 capsid surface, TRIM5 proteins assembles into hexagonal net with 
the SPRY domains centered on the edges and the B-box and RING domains at the vertices 
35
. The 
conformational flexibility of the hexagonal net allows TRIM5α to accommodate the variable 
curvature of retroviral capsids. TRIM5α-capsid interaction results in interference with the capsid 
uncoating process, thereby preventing reverse transcription and transport to the nucleus of the viral 
genome
34,36
. The ubiquitin E3 ligase activity of TRIM5α is required for restriction, however, 
11 
 
TRIM5α-mediated ubiquitination of HIV-1 capsid has not been detected
37
. TRIM5α also binds and 
restricts N tropic mouse leukemia virus (N-MLV)
38
, but the precise mechanism is yet to be 
determined. In addition, it also reported that TRIM5α inhibits retroviral infection by activating innate 
immune signaling. We will discuss it in the below section of TRIM proteins and Innate Immunity. 
  









.  Like TRIM5α, TRIM11 also interacts with HIV-1 capsid. But 
in contrast to TRIM5α, TRIM11 restricts HIV-1 reverse transcription by promotes premature viral 
uncoating
39
. TRIM28 (also known as KAP1) limits HIV-1 by binding the acetylated integrase. The 
acetylation of integrase is essential for the integration of HIV-1 cDNA into the host genome. TRIM28 
mediates integrase deacetylation through the formation of a protein complex which includes the 
deacetylase HDAC1
40
.  TRIM22 restricts HIV infection by two distinct mechanisms. First, TRIM22 
controls the trafficking of the gag protein to the plasma membrane and interferes with assembly of 
new viral particles
41
. Secondly, TRIM22 co-opts with  class II transactivator (CIITA) and Sp1 to 
inhibit viral gene transcription initiation and elongation 
44
. TRIM19, also known as promyelocytic 
leukemia (PML), restricts the HIV virus by reducing the reverse transcription products in the host and 




TRIM proteins-mediated intrinsic immunity to influenza A virus 
Similar to HIV-1, influenza A virus (IAV) is targeted by multiple TRIM proteins. Our laboratory 
reported that TRIM32 is a host intrinsic immune factor to IAV. TRIM32 senses and targets IAV PB1 
polymerase protein for ubiquitination and protein degradation 
25
.  TRIM22, an interferon-stimulated 
gene, also ubiquitinates and degrades IAV nucleoprotein
45
. TRIM56 inhibits the replication of 
influenza viruses by specifically targeting viral RNA synthesis through its C-terminal tail 
46
. 
Furthermore, TRIM25, a critical TRIM in innate immunity (discussed in below section), inhibits IAV 
through a direct mechanism that is independent of its ubiquitin ligase activity and the interferon 
12 
 
pathway. TRIM25 binds IAV ribonucleoproteins and inhibits viral RNA synthesis 
47
(Figure 3). These 
recent studies show that TRIM proteins either target viral proteins for protein degradation or inhibit 
viral RNA synthesis. It is clear that TRIM proteins mediate viral protein degradation through K48-
linked polyubiquitination; however, the mechanism for the inhibition of viral RNA synthesis is 
elusive. As the ubiquitin E3 ligase activity is dispensable, these TRIM proteins might disrupt IAV 
polymerase complex by directly binding NP or other subunit of viral RNP. 
 
TRIM proteins-mediated intrinsic immunity to other viruses 
In addition to IAV, TRIM22 restricts many other viruses (Figure 3). First, Hepatitis B virus is 
inhibited by TRIM22 and TRIM41. TRIM41 inhibits HBV enhancer II activity, which is dependent 
on its E3 ubiquitin ligase activity and the integrity of C-terminal domain 
48
. TRIM22 inhibits HBV by 
suppressing the core promoter responsible for viral pre-genomic RNA synthesis 
49,50
. TRIM22 also 
restricts hepatitis C virus (HCV) by targeting NS5α for ubiquitination and degradation
51
. Similarly, 
TRIM14 inhibits the HCV infection by targeting the NS5α protein for degradation
52
. Japanese 
encephalitis virus (JEV), another virus from the family Flaviviridae, is inhibited by TRIM52. 





 In addition to the viruses mentioned, TRIM22 also restricts encephalomyocarditis virus (EMCV) by 
targeting viral 3C protease for ubiquitination and degradation
50
. Like TRIM22, several TRIM proteins 
are reported to have a broad-spectrum antiviral activity. TRIM19 has been shown to inhibit herpes 
virus and adeno-associated virus
54,55
. TRIM21 restricts adenoviruses and rhinoviruses by proteasomal 
degradation of viral particles
56,57
. TRIM56 restricts IBV, HIV, yellow fever virus and dengue virus by 
reducing the vRNA levels through its C-terminal domain
58-60
. Additionally, TRIM25 mediates K63-
linked ubiquitination of ZAP (zinc finger antiviral protein) to promotes ZAP antiviral activity to 





TRIM PROTEINS & INNATE IMMUNITY 
Innate immune responses are triggered by exogenous microbial products which are common to many 
pathogens but are absent in the host. These microbial products, also known as pathogen-associated 
molecular patterns (PAMPs), engage with the pattern-recognition receptors (PRRs) which either 
present on the cell surface or inside the cells 
64,65
. The engagement activates a series of signal 
cascades to stimulate the expression of a cohort of chemokines, cytokines and genes critical for host 
defense 
66
. PRRs consist of several subgroups, including Toll-like receptor (TLR), RIG-I-like receptor 
(RLR), the cyclic GMP-AMP synthase (cGAS) and NOD-like receptor (NLR). TLR, RLR and cGAS 
signaling pathways converge to the hub, TANK-binding kinase 1 (TBK1) and IKK epsilon (IKKε). 
TBK1 and IKKε phosphorylate the interferon regulatory factors (IRFs) 
67-70
. For example, TBK1 
phosphorylates serines in the C-terminal domain of IRF3, which triggers the dimerization and nuclear 
translocation of IRF3. In the nucleus IRFs form active transcriptional complexes that bind to 
interferon stimulation response elements (ISRE) and activate type I IFN genes expression 
67-71
. Type I 
IFN is the master cytokine in innate immunity and induces mRNA expression of > 300 IFN-
stimulated genes (ISGs), such as protein kinase R, Mx1 and IFITM. Interestingly, some  TRIM 
proteins are ISGs, including TRIM22, TRIM25 and TRIM5
72
. In this section, we discuss the role of 
TRIM proteins in the following innate immune signaling pathways (Fig. 4). 
 
 
TRIM proteins & TLR signaling 
TLRs are membrane proteins residing on cell surface or endosomes. The TLRs on endosomes 
recognize viral nucleic acids. For example, TLR3 detects viral double-strand RNA while TLR7 and 
TLR8 sense viral single-strand RNA 
73
. TLR9 recognizes unmethylated CpG motifs within viral DNA 
73
.  Although all TLRs activates TBK1/IKKε and downstream IRF signaling, they recruit different 
adaptors. TLR3 recruits TRIF whereas TLR7, 8 and 9 relay signals through MyD88
73




Several TRIM proteins regulate TLR signaling pathways. TRIM8 act as an essential regulator of IRF7 
in an E3 ubiquitin ligase independent manner.
74
 TRIM21 (also known as Ro52) has been reported to 
negatively regulates IFN production by targeting IRFs, including IRF3, IRF7 and IRF5 for 
ubiquitination and degradation 
75-77
. However, another study presented an opposite result by showing 
that TRIM21 interferes with the interaction between Pin1 (peptidyl-prolyl cis/trans isomerase, NIMA-
interacting 1) and IRF3, thus preventing IRF3 ubiquitination and degradation
78
 . TRIM protein also 
regulates TLR adaptors. For example, TRIM56 promotes TLR3 activation by interacting with TRIF, 
but its E3 ligase activity is not required 
79
. By contrast, TRIM38 impairs TLR3 signaling by targeting 
TRIF for proteasomal degradation 
80
. In addition, TRIM38 also catalyzes K48-linked 




 and  lysosomal 
dependent degradation of TAB2
83
  to negatively regulate NF-кB signaling pathway. The discovery of 
TRIM protein as a negative regulator of host immune response is important because it represents a 
new self-control mechanism to prevent over-activation of immune response. 
 
TRIM proteins & RLR signaling pathway 
The RLRs, including RIG-I, MDA5 and LGP2, recognize the double-stranded RNA (dsRNA) or 5’ 
triphosphate RNA generated by viral replication of RNA viruses in the cytoplasm 
84-89
. Engagement 
of viral RNA activates RIG-I and MDA5, which bind the mitochondrial antiviral signaling protein 




TRIM proteins & the RIG-I-like receptors 
TRIM proteins play both positive and negative roles in modulating the RLR signaling pathway. 
TRIM25 mediates K63-linked ubiquitination of RIG-I and the polyubiquitin chain stabilizes the 
oligomerization of RIG-I 
24
, which promotes MAVS aggregation and subsequent activation 
96
. 
Similarly, TRIM4 conjugates K63-linked polyubiquitin chains the CARD domain of RIG-I 
97
. 
Interestingly, TRIM25 also synthesizes unanchored K63-linked polyubiquitin chain which helps RIG-
15 
 
I oligomerization and stability to supports the interaction with MAVS
24,98
. MDA5, another RLR, also 
undergoes K63-linked ubiquitination, however, TRIM65 is the cognate ubiquitin E3 ligase. Similar to 
RIG-I ubiquitination, the K63 ubiquitination of MDA5 is critical for MDA5 oligomerization and 
activation 
99
. By contrast, TRIM13 negatively regulate the MDA5-dependent IRF activation although 
it not clear whether the ubiquitin E3 ligase activity is required
100
. In addition, TRIM38 positively 
regulates both RIG-I and MDA5 by SUMOlytion, which prevents K48-linked polyubiquitination and 
degradation
101
.  It is clear that TRIM proteins regulate the activity of the cytosolic RNA sensor, RIG-I 
and MDA5, however, how these TRIM proteins are regulated upon external signal stimulation, such 
as RNA virus infection, is elusive. Furthermore, whether there is functional redundancy of these 
TRIM proteins and how these TRIM proteins coordinate need further investigation. 
 
TRIM proteins & MAVS 
Multiple TRIM proteins have been found to regulate MAVS on the mitochondria with distinct 
outcomes. TRIM31 mediates K63-linked polyubiquitination of MAVS and promotes the formation of 
prion-like aggregates, the active form of MAVS 
102
. TRIM14 bridges NEMO to MAVS by the 
polyubiquitin of TRIM14 to activate IRF3 and NF-кB pathways 
103
. Unexpectedly, one study reported 
that TRIM25 mediated K48-linked polyubiquitination of MAVS, which permits IRF3 signaling but 
inhibits NF-kB, another branch of MAVS signaling
104
. Additionally, TRIM44 has been to show to 











Table 2. Summary of the role of tripartite motif proteins in innate immunity 
TRIM 
protein 
Mode of action 
TRIM4 TRIM4 induces the Lys 63-linked ubiquitination of CARD domain RIG-I, 
which is crucial for the cytosoiic RIG-I signaling pathway 
TRIM5 TRIM5 couples innate viral sensing and CD8+ T-cell activation to increase 
species barriers against retrovirus infection. 
TRIM6 TRIM6 synthesize unanchored K48-Iinked polyubiquitin chains, which activate 
IKKt for subsequent STAT1 phosphorylation. 
TRIM11 TRIM11 inhibits RIG-l-mediated IFN-p production by targeting the TBK1 
signaling complex. Interaction is dependent on CC domain of TRIM11 
TRIM13 TRIM13 enhances RIG-I activation and positively regulate signaling pathway 
TRIM13 TRIM13 regulates the type I interferon response through inhibition of MDA5 
activity 
TRIM14 TRIM14 interacts with MAVS through its SPRY domain and undergoes k63 
linked autoubiquitination and recruits NEMO to the MAVS complex. 
TRIM21 The IRF association domain of IRF5 interacts with TRIM21 via its PRY/SPRY 
domain and mediates its K48 and k63 ubiquitination I regulation. 
TRIM21 TRIM21 interacts with IRF3 through its SPRY domain and inhibits IRF3 
ubiquitination and positively regulates it. 
TRIM21 TRIM21 acts as an E3 ligase and mediates monoubiquitination of IKKþ 
downregulates NF-nB Signalling 
TRIM21 TRIM21 interacts with Fc fragment of swine immunoglobulin G (sFc) fused 
VP1 of FMDV and thereby causing its K4Mnked degradation. 
TRIM23 TRIM23 through itsARF domain Interacts with NEMO resulting in its K27-
17 
 
linked ubiquitination and positively regulate downstream pathway 
TRIM24 T-Cell-lntrinsic TRIM24 is required for IL-ip-mediated activation of TH2 cells 
TRIM25 TRIM25 induces the Lys 63-linked ubiquitination of CARD domain RIG-I, 
which is crucial for the cytosoiic RIG-I signaling pathway 
TRIM25 Short, unanchored. K63-linked ubiquitin chains mediated by TRIM25 activate 
RIG-I 
TRIM25 TRIM25 mediates k48 linked polyubiquitination of MAVS and positively 
regulates IRF3 pathway through regulating oligomerization 
TRIM26 Autoubiquitination of TRIM26 helps TBK1-NEMO interaction and recruits 
TBK1 to the MAVS signalsome. 
TRIM27 TRIM27 negatively regulates signaling involved in the antiviral response and 
inflammation by targeting the IKKs 
TRIM27 TRIM27 mediates K-48 polyubiquitination of PI3KC2P, leading to a decrease 
in PI3K activity and negatively regulate CD4 T cells 
TRIM27 TRIM27 through its SPRY domain interacts with NDB domain of NOD2 
and targets it for K48-linked ubiquitination proteasomal degradation 
TRIM28 TRIM28 acts as a SUMO E3 ligase and negatively regulates IRF7 by 
SUMOylation 
TRIM29 TRIM29 induces NEMO ubiquitination through K48 linkage which results 
in proteasomal degradation and supression of downstream pathway 
TRIM29 TRIM29 targets STING for K48 ubiquitination and degradation and 
negatively regulates STING dependent pathway 
TRlM30a TRIM30a interacts with TAK1-TAB2-TAB3 and promotes the k48 linked 
ubiquitination of degradation of TAB2 and TAB3 thus supressing signaling 
18 
 
TRIM30a TRIM30a prevents TRAF6 autoubiquitination, diminishes IkBo 
phosphorylation and negatively regulates the NF-kB pathway 
TRIM30a TRIM30a promotes the degradation of STING via K48-linked ubiquitination 
and negatively regulates STING dependent pathway 
TRIM30a TRIM30 negatively regulates NLRP3 intlammasome activation by 
modulating and inhibiting ROS production 
TRIM31 TRIM31 interacted with MAVS and catalyzed the Lys63 (K63)-linked 
polyubiquitination and regulates downstream pathway positively 
TRIM31 TRIM31 directly binds to NLRP3, promotes K48-linked polyubiquitination 
and proteasomal degradation of NLRP3. 
TRIM32 TRIM32 targets STING for K63-linked ubiquitination through its E3 ligase 
activity, which promoted the interaction of STING with TBK1. 
TRIM33 TRIM33 targets DHX33 for K63 linked ubiquitination which activates the     
formation of the DHX33-NLRP3 inflammasome complex. 
TRIM38 TRIM38 interacts with and mediates k48 linked ubiquitination and degradation 
of TRIF and negatively regulates TLR3/4 dependent pathway 
TRIM38 TRIM38 activates MDA5- and RIG-I through their SUMOylation which 
enhances dephosphorylation and activation and inhibits its degradation 
TRIM38 TRIM38 targets NAP1 for ubiquitination and subsequent proteasome-mediated 
degradation and supresses IFN-þ response. 
TRIM38 TRIM38 Interacts with TAB2/3 through Its PRY-SPRY domain and mediates 
k48-linked ubiqutination, degradation and translocation 
TRIM38 TRIM38 sumoylates STING during the early phase of viral infection, promoting 
both STING activation and protein stability 
19 
 
TRIM38 TRIM38 binds to TRAF6 and promotes its K48-linked polyubiquitination and 
proteasomal degradation thus supresses downstream pathway 
TRIM44 TRIM44 acts as a deubiquitinase enzyme and prevents k48 linked degradation of 
MAVS positively regulate MAVS dependent pathway 
TRIM56 TRIM56 interacts with TRIF through its C-terminal domain and enhances 
TLR3 pathway in an E3 ligase independent manner. 
TRIM56 TRIM56 interacts with STING and targets it for K63-linked ubiquitination 
which initiates dimerization and facilitates STING–TBK1 interaction 
TRIM56 TRIM56 induces the Lys335 monoubiquitination of cGAS which increases of 
its dimerization, DNA-binding activity and cGAMP production. 
TRIM65 TRIM65 interacts and promotes K63-linked ubiquitination of MDA5 at lysine 
743, which is critical for MDA5 oligomerization and activation. 
TRIM9s TRIM9s undergoes Lys-63-linked autopolyubiquitination and serves as a 
platform to bridge GSK3þ to TBK1, activation of IRF3 signaling. 
FMDV: Foot and mouth disease virus; IKKþ: inhibitor of nuclear factor kappa-B kinase subunit 
beta; MAVS: Mitochondrial antiviral signaling protein; STAT: Signal transducer and activator of 
transcription; TRAF6: TNF receptor-associated factor 6; TRIM: Tripartite motif. 
 
 
TRIM proteins & the TBK1 protein complex 
Several TRIM proteins target the TBK1 kinase complex for IFN regulation. First, TRIM26 undergoes 
autoubiquitination upon viral infection and the polyubiquitin of TRIM26 bridges NEMO to TBK1, 
thus facilitating TBK1 activation 
106
. Secondly, the short form of TRIM9 (TRIM9s) also undergoes 
K63-linked auto-polyubiquitination upon viral infection. The polyubiquitin of TRIM9s serves as a 
20 
 
platform to bridge GSK3β to TBK1, leading to the activation of IRF3 signaling 
107
. Thirdly, TRIM11 
inhibits TBK1 activity by blocking TBK1 interaction with its binding partners, NAP1 and TANK
108
. 
Lastly, TRIM38 facilitates K48 linked polyubiquitination and degradation of NAP1, resulting in a 
reduced activity of IRF3
82
. As the TBK1 kinase complex is the hub of various innate immune 
signaling pathways, whether these TRIM proteins are specific to the RLR signal pathway or also 
work on other innate signaling pathways need to be clarified in the future. 
 
TRIM proteins & cGAS signaling 
Cytosolic viral DNA is recognized by the recently identified DNA sensor, cyclic GMP-AMP synthase 
(cGAS, also known as MB21D1) 
109
. After binding to DNA, cGAS produces cyclic GMP-AMP 
(cGAMP). cGAMP is a second messenger and binds to the endoplasmic reticulum membrane protein, 
stimulator of interferon genes (STING, also known as TMEM173, MPYS, MITA and ERIS), which 
leads the dimerization of STING 
110-112
. Subsequently, STING recruits TANK-binding kinase 1(TBK1) 




TRIM56 and TRIM32 have been reported to catalyze K63-linked polyubiquitination of STING, 
which is essential for activation of IFNβ expression and restriction of DNA viruses 
113,114
. In contrast, 
TRIM30α and TRIM29 promote the degradation of STING via K48-linked ubiquitination through a 
proteasome-dependent pathway
115,116
. Interestingly, TRIM38-meidated sumoylation of STING 
counteracts the K48-linked ubiquitination of STING and prevents STING from protein degradation 
117
. Similarly, TRIM38 also mediates sumoylation of cGAS, thus preventing cGAS polyubiquitination 
and degradation
117
 . Recently, the ubiquitin E3 ligase for STING, TRIM56, is found to catalyze 
monoubiquitination of cGAS, which promotes cGAS dimerization, DNA-binding activity, and 
cGAMP production 
118
. In addition, TRIM21 facilitates the exposure of the viral genome in the 
cytosol, thus sensitizing cGAS and RIG-I signaling 
119
(Figure 4). Notably, TRIM38 and TRIM56 
regulate both cGAS and STING. However, STING is a membrane protein on the ER while cGAS is a 
21 
 
cytosolic and nuclear protein. The subcellular localization of these TRIM proteins and the 
intracellular trafficking of these proteins are the questions that need to be addressed. 
 
TRIM proteins & NLR signaling 
NLRs comprise a family of intracellular sensors which recognize microbial products and mount 
proinflammatory and antimicrobial immune response
120,121
. Upon stimulation, NLR forms 
inflammosomes, a large and highly ordered cytosolic complex, which leads to caspase-mediated 
proteolytic activation and IL-1β and IL-18 
122
.  TRIM33 binds and ubiquitinates DHX33, a cytosolic 
receptor upstream of NLRP3, which facilitates inflammosome activation 
123
. Coiled Coil domain of 
TRIM31 interacts with NACHT domain of NLRP3 and mediates K48-linked ubiquitination that leads 
to the degradation of NLRP3 
124
. TRIM30α negatively regulates NLRP3 inflammasome activation by 
modulating reactive oxygen species production 
125
. In addition, TRIM27 degrades NOD2 and inhibits 
































Figure 4. The role of TRIM proteins in innate immunity This figure illustrates that TRIM proteins 
play both positive and negative roles in TLR, RLR and cGAS signaling pathways. 
cGAS: Cyclic GMP–AMP synthase; RLR: RIG-I-like receptor; TLR: Toll-like receptor; TRIM: 
Tripartite motif. 
 
TRIM proteins & other innate immune signaling pathways 
The NF-кB transcription factors play a critical role in various antiviral immune signaling pathways
129
. 
A wide range of soluble and membrane-bound extracellular ligands activate NF-кB, such as TNF and 
IL-1 etc. Take TNFα signaling for example, the TNF receptor recruits a series of intermediary 
adaptors after TNF stimulation. These adaptors further recruit and activate the IKK kinase complex 
consisting of IKKα, IKKβ and NEMO. The activated IKK complex phosphorylates IкBα, which leads 



































      


































regulated by several TRIM proteins. TRIM23 binds NEMO through the C terminal ARF domain and 
targets NEMO for K27-linked ubiquitination, which leads to increased activation of NF-кB signaling 
130
. By contrast, TRIM30α mediates protein degradation of TAB2/3, the adaptors of TAK1, thus 
inhibiting TAK1 activity and downstream IKK kinase activation 
131
. TRIM21 inhibits the NF-кB 
pathway through mono-ubiquitination of IKKβ 
132
. Several TRIM proteins regulate both NF-кB and 
IRF signaling pathways. For example, TRIM27 inhibits NF-кB and IRF3 via interaction with IKK, 
but the mechanism is not clear 
133





IFN binds IFN receptors to activate JAK (Janus –kinase)-STAT (signal transducer and activator of 
transcription) pathway, which stimulates hundreds of ISGs to execute the antiviral actions. TRIM6 is 
found to catalyze unanchored K48-linked polyubiquitin chains, which activates IKKε to 
phosphorylate STAT1. The phosphorylation results in the induction of a subset of ISGs essential for 




TRIM PROTEINS & ADAPTIVE IMMUNITY 
Most TRIM proteins are found to regulate intrinsic and innate immunity, however, there are also 
several TRIM proteins regulate adaptive immunity. TRIM5 couples innate viral sensing and CD8(+) 
T-cell activation to increase species barriers against retrovirus infection 
136
. TRIM8 is a Th17-specific 
HIV dependency factor and an important anti-HIV factor 
137
. TRIM24 regulates the expression of 
Th2-type cytokines 
138
. TRIM27 inhibits the activation of CD4
+ 
cells through K48-linked 
polyubiquitination of PI3K-C2β 
139
. Additionally, TRIM21 plays an important role in detection of 
antibody opsonized viruses, such as the foot and mouth disease virus (FMDV). TRIM21 binds to the 
highly conserved Fc region of immunoglobulins and targets the virus for degradation by proteasome 
140
. Overall, there are only a few TRIM proteins are discovered to regulate adaptive immunity because 
24 
 
of the limits of research tools. Nonetheless, the list will grow as more animal models for TRIM 
proteins are generated. 
 
TARGETING TRIM PROTEINS: VIRAL EVASION STRATEGY 
 
Targeting TRIM proteins by RNA virus 
The arms race against host defense has forced viruses to evolve new strategies for evasion. Thus, it is 
not a surprise to find some viruses target the TRIM proteins to dampen host de defense. Firstly, 
several RNA viruses target TRIM25, the regulator of RIG-I. The non-structural protein 1 (NS1) of 
Influenza A virus directly interacts with the coiled coil domain of TRIM25, thereby preventing its 
multimerization which is essential for the E3 ligase activity. Defective TRIM25 fails to catalyze K63-
linked ubiquitination of RIG-I, thus blocking type I IFN expression
141,142
. Similarly, the nucleoprotein 
of SARS-associated coronavirus (SARS-CoV), MERS-CoV and the severe fever with 
thrombocytopenia virus (SFTSV) also interact with TRIM25 and prevent TRIM25-RIG-I interaction, 
thereby inhibiting RIG-I signaling
143
. The Non-coding RNAs of PR-2b strain of Dengue virus bind to 
the host TRIM25 and prevents USP15-mediated deubiquitination, which is important for RIG-I 
activation
144,145
. Secondly, TRIM6 is the target of two RNA viruses. The matrix protein of Nipah 
virus induces TRIM6 degradation to suppress TRIM6 –mediated IFN response 
146
 whereas Ebola 
virus utilizes TRIM6 to ubiquitinate its VP35 protein, thereby promoteing VP35 activity and virus 
replication
147
. Lastly, several RNA viruses utilize TRIM proteins to suppress host innate immune 
responses. The NS5 protein of yellow fever virus interacts with TRIM23, which results in K6-linked 
poly-ubiquitination of NS5. The polyubiquitination facilitates NS5 interaction with STAT2, thereby 
inhibiting type I IFN response
148
. JEV upregulates the expression of TRIM21, which suppresses the 
IFN-I response
149
, however, the mechanism is not clear. The vpr protein of HIV-1 negatively 





Targeting TRIM proteins by DNA virus 
Like RNA viruses, DNA viruses also target TRIM protein to subvert immune response by several 
distinct mechanisms. The HBV X protein suppresses TRIM22 mRNA expression by CpG 
methylation of the 5`-UTR of TRIM22 gene
151
. Epstein - Barr virus (EBV) targets TRIM28 for 
phosphorylation at serine residue 824, which impairs antiviral function of TRIM28
152
. In addition, 
several DNA viruses target TRIM proteins for ubiquitination. The ICP0 protein of HSV-1 
ubiquitinates and degrades TRIM27, resulting in the inhibition of immune response
153
. Similarly, 




The co-evolution of host and virus has kept shaping the viral survival strategy and host defense 
system. Although these mechanisms have existed for a very long time, many of them await for 
discovery, including the antiviral mechanism of the TRIM protein family. Since TRIM5a was 
discovered as a species barrier to restrict viral infection, the number of antiviral TRIM proteins had 
kept increasing. Several recent systematic screenings suggest that more TRIM proteins are involved 
in host immunity and viral restriction. Despite of the increasing knowledge of TRIM proteins, there 
are several questions needed to be addressed or directions to be explored in the future. First, what are 
the underlying mechanisms for the broad-spectrum antiviral activity and specificity of TRIM 
proteins? As discussed above, some TRIM proteins, such as TRIM22, TRIM19 and TRIM56, restrict 
multiple viruses. To determine the broad-spectrum antiviral activity, it is important to identify the 
common mechanism. For example, TRIM22 ubiquitinates viral proteins to restrict viral infection. It 
will be interesting to know whether the interacting viral proteins share a common motif for TRIM 
interaction. Conversely, multiple TRIM proteins may attack the same virus. For example, HIV-1 has 
been shown to be limited by several TRIM proteins. However, detailed biochemical and genetic 
analyses are further needed to clarify the functional redundancy among TRIM proteins. Secondly, 
26 
 
how TRIM proteins are activated and regulated upon viral infection? Most studies focus on the 
mechanisms by which TRIM proteins modulate host immunity and viral infection. Little is known 
about the regulatory mechanisms for TRIM proteins. Elucidation of the regulatory mechanism for 
TRIM proteins will help develop a novel strategy to boost host immunity to viral infection. Thirdly, 
the in vivo role of most TRIM proteins is unknown. Recently, several TRIM protein transgenic and 
knockout mice have been generated. These mice are precious tools to study the in vivo role of TRIM 
proteins. However, most of these mouse models have not been examined for viral infection. Lastly, is 
there any inherent relevance of the genetic mutations of TRIM proteins to human immune diseases? 
Genetic mutations in the NHL repeats of TRIM32 cause recessive hereditary muscle disorders, 
including limb girdle muscular dystrophy 2H (LGMD2H) 
155-158
. Recent genome-wide association 
(GWA) studies implied a link of a group of TRIM proteins to the susceptibility of neuropsychiatric 
disorders, developmental diseases, cardiovascular and metabolic diseases
159
. However, whether 
genetic mutations of TRIM proteins dampen human host immune defense is not clear. Taken all 
together, studies in the above directions will open a new spectrum in anti-viral research and will aid 
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Influenza A virus (IAV) is a highly transmissible respiratory pathogen and a major cause of 
morbidity and mortality around the world. Nucleoprotein (NP) is an abundant IAV protein 
essential for multiple steps of the viral life cycle. Our recent proteomic study of the IAV-host 
interaction network found that TRIM41 (tripartite motif-containing 41), a ubiquitin E3 ligase, 
interacted with NP. However, the role of TRIM41 in IAV infection is unknown. Here, we report 
that TRIM41 interacts with NP through its SPRY domain. Furthermore, TRIM41 is constitutively 
expressed in lung epithelial cells, and overexpression of TRIM41 inhibits IAV infection. 
Conversely, RNA interference (RNAi) and knockout of TRIM41 increase host susceptibility to 
IAV infection. As a ubiquitin E3 ligase, TRIM41 ubiquitinates NP in vitro and in cells. The 
TRIM41 mutant lacking E3 ligase activity fails to inhibit IAV infection, suggesting that the E3 
ligase activity is indispensable for TRIM41 antiviral function. Mechanistic analysis further 
revealed that the polyubiquitination leads to NP protein degradation and viral inhibition. Taking 
these observations together, TRIM41 is a constitutively expressed intrinsic IAV restriction factor 














Influenza A virus is a member of the Orthomyxoviridae family and a human respiratory pathogen 
that causes seasonal epidemics and occasional global pandemics with considerable economic and 
social impact 
1,2
. Virus engages with the host cellular protein interaction network during infection. 
The engagement either facilitates virus hijack of host molecular machinery to fulfill viral life 
cycle or triggers host immune defense to eliminate the virus. In recent years, host intrinsic 
restriction factors are gaining increasing importance in IAV inhibition 
3
. Host intrinsic restriction 
factors usually limit viral infection by direct interaction with viral proteins. For example, 
plakophilin 2 (PKP2) competes with PB2 for PB1 binding, thus disrupting IAV polymerase 
complex and inhibiting viral replication 
4
. The therapeutics targeting at intrinsic immunity factors 
are more promising because cellular proteins are less likely to mutate under drug-mediated 
selective pressure.  
 
The tripartite motif (TRIM) family members have been increasingly recognized as intrinsic 
immunity factors that inhibit viral infection. For example, TRIM5α is well known for the species-
specific retroviral restriction by binding to the viral capsid and inducing premature uncoating 
5
. 
TRIM79α restricts tick-borne encephalitis virus 
6
. TRIM28, also known as KAP1, restricts 
murine leukemia virus as well as facilitates the establishment of viral latency 
7,8
. Recently, 
TRIM52 has been found to interact with the NS2A protein of Japanese encephalitis virus and 




Several TRIM proteins have been found to inhibit IAV infection. For example, TRIM32 
ubiquitinates PB1 and subsequently degrades PB1, thereby limiting viral infection 
10
. TRIM19 
(also known as PML), TRIM22 and TRIM56 display a broad intrinsic antiviral activity and 
inhibit multiple viruses, including IAV 
11-13
. By contrast, IAV evolves to subvert host immunity 
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by targeting TRIM proteins 
14
. TRIM25 ubiquitinates and activates RIG-I-mediated innate 
immunity 
15
. The NS1 of IAV impairs interferon (IFN)-dependent innate immune response by 




Our recent study on the IAV-host protein interaction network found that TRIM41 interacted with 
the NP 
4
. TRIM41, also known as the RING finger-interacting protein with C kinase (RINCK), 
regulates PKC kinase signaling 
18
. TRIM41 is also found to interact with the nucleotide binding 
oligomerization domain containing 2 (NOD2), but how TRIM41 regulates NOD2 signaling is not 
clear 
19
. Recently, a screening of TRIM proteins found that TRIM41 along with other seven 
TRIM proteins inhibited hepatitis B virus (HBV) transcription 
20
.  However, the role of TRIM41 
in IAV infection is unknown. Here, we characterized the physical interaction between TRIM41 
and NP. Furthermore, overexpression of TRIM41 inhibits IAV infection while depletion of 
TRIM41 increases host susceptibility to viral infection. As a ubiquitin E3 ligase, TRIM41 
ubiquitinates NP and the ubiquitination leads to NP protein degradation. Thus, our study 











MATERIALS AND METHODS 
Cells and viruses. HEK293 cells (ATCC, # CRL-1573) and MDCK cells (ATCC, # CCL-34) 
were maintained in Dulbecco’s Modified Eagle Medium (Life Technologies) containing 
antibiotics (Life Technologies) and 10% fetal bovine serum (Life Technologies). A549 cells 
(ATCC, # CCL-185) were cultured in RPMI Medium 1640 (Life Technologies) plus 10% fetal 
bovine serum and 1X MEM Non-Essential Amino Acids Solution (Life Technologies). Primary 
human tracheal epithelial cells and supporting medium were purchased from Lifeline Technology 
(Frederick, MD) (# FC-0035 and # LL-0023).  
 
Influenza A/Puerto Rico/8/34 (H1N1) (Charles River Laboratories, # 10100374), A/WSN/33 
(H1N1) (a kind gift of Dr. Peter Palese, Mount Sinai School of Medicine, NY), and A/New 
York/18/2009 (H1N1) pdm09 (BEI Resources). Influenza PR8-GLuc virus was a generous gift 
from Dr. Peter Palese and features a Gaussia luciferase (Gluc) gene inserted downstream of PB2 
23
. IAV propagation in specific pathogen-free fertilized eggs and TCID50 assay was performed as 
described by Szretter et al.  
37
. Sendai virus with a luciferase gene (SeV-Luc) was a kind gift from 
Dr. Charles Russell (St. Jude’s Hospital, Memphis, TN). VACV with a firefly luciferase gene 
(VACV-Luc) was a gift from D.L. Bartlett (University of Pittsburg, Pittsburg, PA). 
 
Plasmids and antibodies. Human TRIM41-HA was a generous gift from Dr. Adolfo Garcia-
Sastre (Mount Sinai School of Medicine, NY) 
30
. TRIM41 was cloned into pCMV-3Tag-8 
(Strategene) to generate TRIM41-FLAG 
38
. Deletion mutant of TRIM41-FLAG was constructed 
using a Q5
®
 Site-Directed Mutagenesis Kit (New England Biolabs). 
 
Anti-β-actin (Abcam, # ab8227), anti-FLAG (Sigma, # F3165), anti-IFITM3 (GeneTex, 
GTX63349), anti-ubiquitin (Santa Cruz Biotechnology, # sc-8017), anti-TRIM41 (Aviva Systems 
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Biology, # ARP34763_P050), anti-HA epitope (Cell Signaling Technology, # 3724), anti-NP 
(BEI resources, # NR-4282), anti-NP (EMD Millipore, # MAB8800), anti-NP (Genscript, # 
A01506-40). Goat anti-Mouse IgG-HRP (Santa Cruz Biotechnology, # sc-2055), Goat anti-
Rabbit IgG-HRP (Santa Cruz Biotechnology, # sc-2030), Alexa Fluor 594 Goat Anti-Mouse IgG 
(H+L) (Life Technologies, # A11005), Alexa Fluor 488 Goat Anti-Rabbit IgG (H+L) (Life 
Technologies, # A11034). 
 
Sample preparation, western blotting and immunoprecipitation. Approximately 1 X 10
6
 cells 
were lysed in 500 µl of tandem affinity purification (TAP) lysis buffer [50 mM Tris-HCl (pH 
7.5), 10 mM MgCl2, 100 mM NaCl, 0.5% Nonidet P40, 10% glycerol, Complete EDTA-free 
protease inhibitor cocktail tablets (Roche)] for 30 min at 4⁰C. The lysates were then centrifuged 
for 30 min at 15,000 x g. Supernatants were collected and mixed with 1X Lane Marker Reducing 
Sample Buffer (Thermo Fisher Scientific). Western blotting and immunoprecipitation were 




Immunofluorescence assay. Cells were cultured in the Lab-Tek II CC2 Chamber Slide System 
4-well (Thermo Fisher Scientific). After the indicated treatment, the cells were fixed and 
permeabilized in cold methanol for 10 min at -20 ⁰C. Then, the slides were washed with 1 X PBS 
for 10 min and blocked with Odyssey Blocking Buffer (LI-COR Biosciences) for 1 h. The slides 
were incubated in Odyssey Blocking Buffer with appropriately diluted primary antibodies at 4 ⁰C 
for 12 h. Images were captured and analyzed using an iRiS
TM
 Digital Cell Imaging System 
(Logos Biosystems). 
 
Real-time PCR. Total RNA was prepared using RNeasy columns (Qiagen). 1 µg quantity of 
RNA was transcribed into cDNA using a QuantiTect reverse transcription kit (Qiagen). For one 
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real-time reaction, 10 µl of SYBR Green PCR reaction mix (Eurogentec) including a 1/10 volume 
of the synthesized cDNA plus an appropriate oligonucleotide primer pair were analyzed on a 
7500 Fast Real-time PCR System (Applied Biosystems). The comparative Ct method was used to 
determine the relative mRNA expression of genes normalized by the housekeeping gene 
GAPDH. The primer sequences: IP10, forward primer 5`- TTCAAGGAGTACCTCTCTCTAG-
3`, reverse primer 5`- CTGGATTCAGACATCTCTTCTC- - 
CAGCAATTTTCAGTGTCAGAAGC-3`, reverse primer 5`- TCATCCTGTCCTTGAGGCAGT-
3`; TRIM41, forward primer 5`- AGAATCCAGGAGCCACAAAC-3`, reverse primer 5`-
TCTTCAGCCAGAAACCGTG-3`; GAPDH, forward primer 5`- AGGTGAAGGTCGGAGTCA-
3`, reverse primer 5`-GGTCATTGATGGCAACAA-3`. 
 
Plasmid transfection. Plasmid transfection. HEK293 cells were transfected using 
Lipofectamine 2000 or Lipofectamine 3000 transfection reagent (Life Technologies) according to 
the manufacturer's protocol. For coimmunoprecipitation experiments, a total of 2.5 μg of 
plasmids was transfected into approximately 1.2 × 10
6
 cells. For other experiments, a total of 0.5 




RNAi depletion. RNAi target sequences (sense strand): TRIM41 siRNA #1: 
GAGGCGAGTGACAGAACTGAA; TRIM41 siRNA #2: AAGGCGTGCTGTGGAAATAAA; 
TRIM41 siRNA #3: TTCAATAGGTGTGAAGAGGTA. siGENOME Non-Targeting Control 
siRNA (Dharmacon, # D-001210-02-05) was used as the control siRNA. siRNA duplexes were 
transfected into A549 cells (5 pmol) using Lipofectamine RNAiMAX Transfection Reagent (Life 




Cell viability. Cell viability was assessed by using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega) according to the manufacturer’s instructions. 
 
CRISPR/Cas9. The single guide RNA (sgRNA) sequence targeting human TRIM41 is: 
GTAGTCTTCATCCCGCATGG. The sgRNA was cloned into lentiCRISPR v2 
24
 (Addgene).  
The lentiviral construct was transfected into HEK293 cells using Lipofectamine 2000. Cells were 
selected with 10 µg/ml puromycin for 14 days. Single clones were expanded for knockout 
confirmation by western blotting and DNA sequencing.  
 
In vitro ubiquitination. In vitro ubiquitination assay was performed according to the 
manufacturer’s manual (Boston Biochem). Ubiquitin (3 μg), E1 (200 ng), UBCH5A (300 ng) 
(Boston Biochem), NP-FLAG (0.5 µg) bound to the anti-FLAG resin (Sigma) and TRIM41-HA 
or ∆RING-HA (0.5 µg) were incubated at 30°C in the ubiquitin assay buffer (20 mM Tris-HCl 
pH 7.5 plus 1 x ERS buffer) for 2 h. Two hours later, the anti-FLAG resin was washed with 1 M 
urea for 15 min to exclude potential binding of unanchored polyubiquitin. Then the resin was 
incubated with 40 μL of 0.2 μg/ml FLAG peptide to elute NP protein. The eluates were 
subsequently analyzed by SDS-PAGE followed by western blotting. 
 
Statistical analysis. The sample size was sufficient for data analysis using paired two-tailed 
Student’s t-test. For all statistical analysis, differences were considered to be statistically 










TRIM41 interacts and co-localizes with NP. Our previous proteomics study showed that 
TRIM41 associated with NP, but the interaction is not well defined (4). Thus, we first validated 
the protein interaction between TRIM41 and NP. FLAG-tagged NP from influenza A/Puerto 
Rico/8/1934 (PR8) or A/New York/1682/2009 (NY) was co-transfected with HA-tagged TRIM41 
into HEK293 cells. Co-immunoprecipitation confirmed the interaction between TRIM41 and the 
two NP proteins (Fig. 5).  
                                
Figure.5: TRIM41 – NP interaction. TRIM41-HA (1.25 μg) was cotransfected with 1.25 μg of 
FLAG-tagged NP from the IAV PR8 or NY strain into HEK293 cells. Cell lysates were 
immunoprecipitated (IP) with anti-FLAG antibody or control IgG and then blotted as indicated. 






Next, we examined NP-TRIM41 protein interaction during viral infection. A549 cells were 
infected with 1 MOI of PR8 IAV for 12 hr, and then cell lysates were immunoprecipitated with 
anti-NP antibody or control IgG. As shown in Figure 2, viral NP interacted with endogenous 
TRIM41. Furthermore, RNase treatment had little effects on this interaction (Fig. 6), suggesting 
NP-TRIM41 interaction is independent of RNA.  
                                          
Figure 6: RNA independent TRIM41- NP interaction.  A549 cells were infected at an MOI of 
1 with PR8 IAV for 12 h. Cell lysates were treated with or without RNase A and then 








We also examined the co-localization between TRIM41 and NP in A549 lung epithelial cells. 
Consistent with a previous report (21), endogenous TRIM41 was expressed in the cytoplasm and 
nucleus (Fig. 7). Following IAV infection, NP was expressed and co-localized with TRIM41 in 




Figure 7: TRIM41- NP co-localization. A549 cells were mock infected or infected with PR8 
IAV. After 12 h, cells were fixed with cold methanol and incubated with anti-NP and anti-











Finally, to determine which domain of TRIM41 is required for NP interaction, we generated a 
series of TRIM41 truncates by mutagenesis (Fig.8).  
 
     
 
Figure 8: The schematics of TRIM41 mutants. RING, really interesting new gene; B-Box, B-








As shown in Figure 9, deletion of RING, the region of amino acid 61-222, B-box, or coiled-coil 
(CC) had little effects on TRIM41-NP interaction while deletion of SPRY abolished the 
interaction suggesting that the C-terminal SPRY domain is required. Indeed, the SPRY domain 
alone is sufficient for NP interaction. Thus, TRIM41 interacts with NP through the SPRY domain 
on the C-terminus. 
 
                 
 
Figure 9: TRIM41 interacts with NP through the SPRY domain.  HA-tagged NP (NP-HA; 
1.25 μg) was cotransfected with 1.25 μg of the indicated FLAG-tagged TRIM41 mutants into 
HEK293 cells. Cell lysates were immunoprecipitated with anti-FLAG antibody and blotted with 
the indicated antibodies. WB, Western blotting. 
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TRIM41 expression is not induced by type I interferon (IFN) 
 As IAV is intrinsically sensitive to the antiviral action of IFN, we speculated that type I IFN 
might regulate TRIM41 expression. Therefore, we treated the cells with IFN or infected A549 
lung epithelial cells with the PR8 IAV mutant with NS1 gene deletion (PR8 ∆NS1) (22). TRIM41 
mRNA and protein expression were then examined. However, IFN stimulation or IAV infection 
marginally modulates TRIM41 protein and mRNA levels (Figs. 10-13), suggesting that TRIM41 
is constitutively expressed in A549 human lung epithelial cells. 
 
                                        
 
Figure 10: Effect of Interferon treatment on TRIM41 expression. A549 cells were treated 
with the designated units (U) of IFN-β for 12 h. Cell lysates were blotted with the indicated 





                 
Figure 11: Effect of IAV infection on TRIM41 expression. A549 cells were infected at the 
indicated MOI with PR8 ΔNS1 IAV for 12 h. Cell lysates were blotted with the indicated 




             
 
Figure 12: Effect of IAV infection on TRIM41 mRNA levels. A549 cells were infected at the 
indicated MOI with the ΔNS1 mutant virus for 4 h. mRNA was extracted, and real-time PCR was 
performed to determine the relative levels of the indicated genes. IFN-β and IFN-γ-inducible 




       
Figure 13: Effect of interferons on TRIM41 mRNA levels. A549 cells were treated with 1 unit 
of IFN-β for the designated times. mRNA was extracted, and real-time PCR was performed to 
determine the relative levels of the indicated genes. All experiments were biologically repeated 
three times. RANTES (regulated on activation, normal T cell expressed and secreted) and IP10 
were the positive controls. 
TRIM41 limits IAV infection.  
These initial observations led to our working hypothesis that TRIM41 modulates IAV infection. 
To test this hypothesis, four assays (reporter assay, western blotting, immunofluorescence and 
TCID50 assay) were adopted to evaluate the biological effects of TRIM41 overexpression on 
IAV infection. First, FLAG-tagged TRIM41 or vector was transfected into HEK293 cells, 
followed by infection with the PR8-Gaussia luciferase reporter virus (PR8-Gluc) (23). Reporter 
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assay showed that TRIM41 overexpression inhibited IAV replication activity (Fig. 10). We also 
examined whether TRIM41 restricted other viruses. HEK293 cells expressing TRIM41-FLAG 
were also infected with two other reporter viruses, sendai virus with a firefly luciferase gene 
(SeV-Luc) or vaccinia virus with a firefly luciferase gene (VACV-Luc). TRIM41 selectively 
restricted IAV replication (Fig. 14). 
                       
Figure 14: TRIM41 selectively restricted IAV replication. HEK293 cells transfected with 0.5 
μg of TRIM41-FLAG or pCMV-3Tag-8 vector were infected at an MOI of 0.1 with IAV-Gluc, 
SeV-Luc, and VACV-Luc for 12 h. Relative luciferase activities were examined. Data represent 
means ± standard deviations of three independent experiments. The P value was calculated (two-
tailed Student's t test) by comparison of results with those with the vector control (*, P < 0.05). 
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We then determined the effect of TRIM41 overexpression on viral infection by examining NP 
expression of PR8 IAV and A/WSN/1933 (WSN). TRIM41 overexpression impaired the 
replication of both IAV strains, as indicated by decreased levels of NP protein (Figs. 15-16). 
                                                     
Figure 15: Effect of TRIM41 overexpression on PR8 IAV nucleoprotein. HEK293 cells were 
transfected with 0.5 μg of pCMV-3Tag-8 vector or TRIM41-FLAG for 24 h and then infected at 
an MOI of 1 with PR8 IAV for 12 h. Cell lysates were blotted using the indicated antibodies. 
64 
 
   
Figure 16: Effect of TRIM41 overexpression on WSN IAV nucleoprotein. HEK293 cells were 
transfected with 0.5 μg of pCMV-3Tag-8 vector or TRIM41-FLAG for 24 h and then infected at 










Immunofluorescence assay (IFA) was also performed to visualize viral restriction. Ectopic 
expression of TRIM41 restricted NY IAV infection in HEK293 cells, indicated by the number of 
infected cells (Fig. 17). 
 
 
Figure 17: Effect of TRIM41 overexpression on NY IAV. HEK293 cells were transfected with 
0.5 μg of pCMV-3Tag-8 vector or TRIM41-FLAG for 24 h and then infected at an MOI of 1 with 
NY IAV for 12 h. Fixed cells were stained with anti-NP antibody. The percentage of stained cells 





TCID50 assay was used to determine the effect of TRIM41 on the production of infectious IAV 
particles. Overexpression of TRIM41 consistently reduced viral titers of WSN IAV (Fig. 18). 
Taken together, these findings indicate that TRIM41 is an IAV restriction factor. 
 
 
     
Figure 18: Effect of TRIM41 overexpression on IAV titers.  HEK293 cells were transfected 
with 0.5 μg of pCMV-3Tag-8 vector or TRIM41-FLAG. After 24 h, cells were infected at an 
MOI of 0.001 with WSN/33 IAV. After the designated hour post infection (h.p.i.), virus titers 




TRIM41 deficiency increases host susceptibility to IAV.  
To complement the above gain-of-function, we first depleted TRIM41 using the small interfering 
RNA (siRNA).  
                                                 
Figure 19: Knockdown of TRIM41 using RNA interference. A549 cells were transfected with 
5 pmol of a scrambled control siRNA or three different siRNA duplexes against TRIM41. After 








Three pairs of siRNA duplex against TRIM41 were individually transfected into A549 cells. 
After 48 h, cells were infected with PR8-Gluc IAV for 12 h. Reduced TRIM41 protein expression 
was correlated with increased IAV reporter activity in A549 lung cells (Figs.20). 
 
                                
Figure 20: Effect of TRIM41 knockdown on PR8 IAV infection. A549 cells were transfected 
with 5 pmol of the control siRNA or the indicated siRNA duplex against TRIM41. After 48 h, the 
cells were infected at an MOI of 0.1 with IAV PR8-Gluc for 12 h. Relative luciferase activities 
were examined. All experiments were biologically repeated three times. Data represent means ± 
standard deviations of three independent experiments. The P value was calculated (two-tailed 




Silencing TRIM41 also enhanced IAV propagation in A549 cells, as detected by IFA and western 
blotting (Figs. 21-22). 
                                                 
 
Figure 21: Effect of TRIM41 knockdown on WSN IAV nucleoprotein. A549 cells were 
transfected with 5 pmol of the control siRNA or the TRIM41 siRNA 2 or 3 duplex for 48 h and 










Figure 22: Effect of TRIM41 knockdown on NY IAV infection. A549 cells were transfected 
with 5 pmol of the control siRNA or the TRIM41 siRNA 3 duplex for 48 h and then infected at an 
MOI of 0.1 with NY IAV for 12 h. Fixed cells were stained with anti-NP antibody. The 







Furthermore, we knocked down TRIM41 in human primary tracheal cells and then infected these 
cells with PR8-Gluc IAV. Luciferase assays showed that RNAi depletion of TRIM41 increased 
IAV infection in primary tracheal cells (Fig. 23). 
 
                                       
Figure 23: Effect of TRIM41 knockdown on PR8 IAV infection in primary cells. Primary 
human tracheal epithelial cells were transfected with 5 pmol of the control siRNA or the TRIM41 
siRNA 3 duplex. After 48 h, the cells were infected at an MOI of 0.1 with PR8-Gluc for 16 h. The 
relative luciferase activity was examined. Data represent means ± standard deviations of three 




Knockout of TRIM41 increases host susceptibility to IAV infection 
We next examined the effects of TRIM41 knockout on IAV infection. In this regard, a single 
guide RNA (sgRNA) was cloned into the lentiCRISPR v2 containing Cas9 (24) and transfected 
into HEK293 cells. After 48 h, cells were selected using puromycin. Single clones were picked 
and expanded for knockout confirmation by western blotting. TRIM41 expression is abolished in 
the CRIPSR knockout clone #4 as shown by western blotting (Fig. 24). DNA sequencing found a 
1-base pair insertion in the DNA genome of the knockout clone #4.   
                                             
Figure 24: TRIM41 knockout using CRISPR – CAS9 technique. CRISPR knockout of 





The increase in PR8-GLuc reporter activity was noted in TRIM41 knockout cells compared to 
wild type controls (Fig. 25). 
                                      
Figure 25: Effect of TRIM41 knockout on PR8 IAV infection. Wild-type (WT) HEK293 and 
TRIM41 knockout (KO) cells were infected at an MOI of 0.1 with IAV PR8-Gluc for 12 h. 
Relative luciferase activities were examined. All experiments were biologically repeated three 






In line with these results, significantly more TRIM41 knockout cells were stained with anti-NP 
antibody (Fig. 26). 
 
       
Figure 26: Effect of TRIM41 knockout on NY IAV infection. Wild-type and TRIM41 
knockout cells were infected at an MOI of 1 with NY IAV for 12 h. Cells were fixed and stained 






We also evaluated the impact of TRIM41 on viral propagation using TCID50 assay. As predicted, 
TRIM41 knockout cells produce more infectious viral particles than control HEK293 cells (Fig. 
27). 
 
            
Figure 27: Effect of TRIM41 knockout on WSN IAV titers. Wild-type and TRIM41 knockout 
cells were infected at an MOI of 0.001 with WSN/33 IAV. After the designated hour 
postinfection, virus titers were determined by TCID50 assay in MDCK cells. All experiments 
were biologically repeated three times. 





Ubiquitin E3 ligase activity is required for TRIM41 antiviral function 
 RING domain is critical for the E3 ligase function of TRIM proteins. Thus, we evaluated the role 
of the RING domain in TRIM41-mediated viral restriction. TRIM41 or the RING deletion 
(∆RING) mutant was transfected into HEK293 cells followed by IAV infection. Ectopic 
expression of wild type TRIM41 attenuates infection with the IAV reporter virus while the 
∆RING mutant failed to defend against IAV infection (Fig. 28). 




Figure 28: Effect of deletion of RING domain on anti-IAV action of TRIM41. HEK293 cells 
were transfected with 0.5 μg of pCMV-3Tag-8 vector, FLAG-tagged TRIM41, or the ΔRING 
mutant. After 24 h, cells were infected at an MOI of 0.1 with PR8-Gluc for 12 h. Relative 
luciferase activities were examined. Data represent means ± standard deviations of three 
independent experiments. The P value was calculated by two-tailed Student's t test (*, P < 0.05). 
 
Furthermore, wild type TRIM41, but not the mutant, restored antiviral activity in the TRIM41 
knockout cells (Fig. 29). 
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Figure 29: Effect of RING domain deletion on TRIM41 anti-IAV action in knockout cells.  
TRIM41 knockout cells were transfected with 0.5 μg of pCMV-3Tag-8 vector, TRIM41-FLAG, 
or the ΔRING mutant for 24 h and then infected at an MOI of 1 with NY IAV for 12 h. HEK293 
cells were included as the control. IFA was performed, and the percentage of stained cells was 
used to determine the infection activity. *, P < 0.05. 
Similarly, the mutant failed to inhibit IAV infection in the TRIM41 knockout cells as determined 
by TCID50 assay (Fig. 30). 
                
Figure 30: Effect of TRIM41 RING domain deletion on WSN IAV titers. TRIM41 knockout 
cells were transfected with 0.5 μg of pCMV-3Tag-8 vector, TRIM41-FLAG, or the ΔRING 
mutant. After 24 h, cells were infected at an MOI of 0.001 with WSN/33 IAV. After the 
designated hour post infection, virus titers were determined by TCID50 assay in MDCK cells. All 
experiments were biologically repeated three times. 
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Thus, we concluded that E3 ligase activity is critical for the antiviral activity of TRIM41. 
TRIM41 ubiquitinates and degrades NP  
The requirement of E3 ligase activity implicates that TRIM41 may ubiquitinate NP. To determine 
whether TRIM41 can couple ubiquitin onto NP, we first performed an in vitro ubiquitination 
assay. TRIM41 is able to heavily conjugate ubiquitin onto NP in vitro, but the ∆RING mutant 
failed to conjugate ubiquitin onto NP (Fig. 31). 
                        
Figure 31: TRIM41 mediated in vitro ubiquitination of NP. In vitro ubiquitination of NP by 
TRIM41. FLAG-tagged NP, HA-tagged TRIM41, and the RING deletion mutant plus E1, E2 
(UBCH5A), ATP, and ubiquitin were added as indicated and incubated at 30°C for 2 h. Samples 
were blotted with the indicated antibodies. Ub, ubiquitin. 
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We next examined NP ubiquitination in cells. NP was transfected with vector, TRIM41 or the 
∆RING mutant into HEK293 cells. As shown in Figure 7B, TRIM41 increased the levels of NP 
ubiquitination. However, ectopic expression of the ∆RING mutant showed little or no effect on 
NP ubiquitination (Fig. 32). 
                         
Figure 32: TRIM41 mediated polyubiquitination of NP. NP-FLAG (0.5 μg) was cotransfected 
with 2 μg of vector, TRIM41-HA, or the HA-tagged ΔRING mutant into HEK293 cells. Cells 
were treated with 1 μM MG132 for 12 h to prevent NP protein degradation. Cell lysates were 




We also examined whether overexpression of TRIM41 increases NP ubiquitination during IAV 
infection. HEK239 cells were transfected with vector or TRIM41, and then infected with 1 MOI 
of PR8 IAV for 12 h. As shown in Figure. 33, TRIM41 increased the levels of NP ubiquitination 
during IAV infection. 
            
Figure 33: TRIM41 mediated polyubiquitination of NP in cells. HEK293 cells were 
transfected with 2.5 μg of vector or TRIM41. After 24 h, cells were infected at an MOI of 1 with 
PR8 IAV and treated with 1 μM MG132 for 12 h. Cell lysates were immunoprecipitated with 
anti-NP antibody and blotted with the indicated antibodies. 
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Consistently, ubiquitinated NP was barely detected in TRIM41 knockout cells (Fig. 34). 
 
                     
 
Figure 34: Effect of TRIM41 knockout on NP ubiquitination. Wild-type and TRIM41 
knockout cells were transfected with 0.5 μg of NP-FLAG. Cell lysates were immunoprecipitated 




Proteins modified with polyubiquitin are classic targets for proteasomal degradation. To 
determine the role of TRIM41 in NP protein turnover, we transfected HEK293 cells with NP 
together with wild type TRIM41 or the ∆RING mutant. Wild type TRIM41, but not the mutant, 
reduced NP protein expression (Fig. 35), indicating that the presence of TRIM41 has a 
destabilizing effect on NP expression. 
        
Figure 35: Effect of TRIM41 RING domain deletion on NP degradation. NP-HA (0.25 μg) 
was cotransfected with the designated amounts of FLAG-tagged TRIM41 or the ΔRING mutant 






To corroborate the role of TRIM41 in NP degradation, HEK293 cells were transfected with NP 
along with TRIM41 or vector. After 24 h, cells were treated with the protease inhibitor MG132 
for 12 h. Western blotting found that MG132 prevented TRIM41-mediated NP degradation (Fig. 
36). 
 
                 
Figure 36: TRIM41 mediated degradation of NP. NP-HA (0.25 μg) was cotransfected with 
0.25 μg of vector or TRIM41-FLAG into HEK293 cells. After 24 h, cells were treated with 





Taken together, the combined data indicate that TRIM41 mediates ubiquitination of NP, which 
leads to NP degradation and viral inhibition. 
DISCUSSION 
The innate immune system uses the pattern recognition receptors (PRRs) in different cellular 
compartments to discriminate microbial components that mark invading viruses. Many of these 
PRRs have been characterized, including the Toll-like receptors (TLRs) and RIG-I-like receptors 
(RLRs) 
25,26
. TLRs and RLRs sense viral nucleic acids and indirectly inhibit viral infection by 
eliciting signaling cascades that activate the expression of type I IFN. The type I IFN acts as a 
master cytokine that activates hundreds of interferon-stimulated genes (ISGs), which in turn 
inhibits viral infection. For example, the interferon-induced transmembrane proteins (IFITMs) 
recruits and coordinates with the zinc metalloprotease ste24-like protein (ZMPSTE24) to block 
influenza virus entry on endosomes 
27,28
. By contrast, intrinsic immunity impairs viral infection 
by direct interaction between host factors and virus 
3
. Several TRIM proteins have been reported 




 and TRIM22 
12
. Similarly, our study 
demonstrates that TRIM41 directly restricts viral infection through ubiquitination of NP. Thus, 
TRIM41 is a new intrinsic immune factor that inhibits IAV infection. 
 
TRIM proteins are ubiquitin E3 ligases that share a conserved N-terminal tripartite motif 
(comprising RING, B-box and coiled-coil) and a versatile C-terminal domain 
29-32
. TRIM41 
belongs to the subgroup of TRIM family that possesses a SPRY domain on the C-terminus. Our 
data showed that the SPRY of TRIM41 is responsible for the interaction with NP. More 
importantly, the RING domain of TRIM proteins confers the ubiquitin E3 ligase activity. Our 
study found the requirement of E3 ligase activity for TRIM41 antiviral activity. Interestingly, a 





but the antiviral mechanism is unknown. However, our study further revealed that TRIM41 
mediates the ubiquitination of NP, which leads to NP protein degradation and viral inhibition.  
 
NP has an essential role in the IAV life cycle, including nuclear transport of vRNP, transcription 
and replication of the viral genome 
3
. Several host factors have been shown to inhibit IAV 
infection by interacting with NP. For example, the myxovirus resistance protein 1 (Mx1) interacts 
with NP and suppresses the influenza virus transcription 
33
. RuvB-like protein 2 (RUVBL2) 
disrupts vRNP assembly by interfering with NP oligomerization 
34
. Interferon stimulated gene 20 
(ISG20) interacts with NP and inhibits viral protein expression 
35
. Similarly, our study showed 
that TRIM41 modulates IAV infection by interaction with NP, which grants NP ubiquitination 
and subsequent protein degradation.   
 
TRIM22 was also reported to ubiquitinate NP and target it for protein degradation 
12
. Unlike 
TRIM41, TRIM22 is an IFN-stimulated gene and the previous showed that the protein expression 
of TRIM22 is very low or undetectable in cells without IFN stimulation. Thus, TRIM22 might 
not be present in the cells during the early stage of viral infection before host IFN response is 
elicited. By contrast, TRIM41 is constitutively expressed and its expression is not modulated by 
IFN and IAV. Therefore, it is possible that TRIM41 and TRIM22 cooperate to limit NP 
expression at different stages of IAV life cycle. Future experiments will investigate the distinct 
roles of TRIM41 and TRIM22 in IAV restriction. Furthermore, CNOT4 is also reported to 
ubiquitinate NP 
36
. However, CNOT4-mediated ubiquitination promotes viral RNA replication by 









We demonstrate that TRIM41 inhibits IAV by targeting NP for proteasomal degradation and 
provides intrinsic cellular restriction against IAV infection. Up-regulation of TRIM41 E3 ligase 
activity may boost host immunity to limit viral infection. Thus, future investigation of the 
regulation of TRIM41 activity might provide the insights and opportunities needed for therapeutic 
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Vesicular stomatitis virus (VSV) is a zoonotic, negative-strand RNA virus of the family 
Rhabdoviridae. The nucleoprotein (N) of VSV protects the viral genomic RNA and plays an 
essential role in viral transcription and replication, which makes the nucleoprotein an ideal target 
of host defense. However, whether and how host innate/intrinsic immunity limits VSV infection 
by targeting the N protein are unknown. In this study, we found that the N protein of VSV (VSV-
N) interacted with a ubiquitin E3 ligase, tripartite motif protein 41 (TRIM41). Overexpression of 
TRIM41 inhibited VSV infection. Conversely, depletion of TRIM41 increased host susceptibility 
to VSV. Furthermore, the E3 ligase defect mutant of TRIM41 failed to limit VSV infection, 
suggesting the requirement of the E3 ligase activity of TRIM41 in viral restriction. Indeed, 
TRIM41 ubiquitinated VSV-N in cells and in vitro. TRIM41-medaited ubiquitination leads to the 
degradation of VSV-N through proteasome, thereby limiting VSV infection. Taken together, our 
study identifies TRIM41 as a new intrinsic immune factor against VSV by targeting the viral 
nucleoprotein for ubiquitination and subsequent protein degradation. 
 
INTRODUCTION 
Vesicular stomatitis virus (VSV) belongs to the Rhabdoviridae that encapsidates a single-
stranded RNA genome encoding five major proteins 
1
. VSV is a zoonotic virus with epidemic 
potential in horses, cattle, and swine, which causes significant economic burden to the livestock 
industry 
2
. To infect host cells, VSV binds to the cell receptors through its glycoprotein (G), 
which triggers endocytosis followed by uncoating of the helical nucleocapsid (NC) in the 
cytoplasm. The nucleoprotein (N) encapsidates the viral RNA to form the NC, which is the 
template for full-length NC replication and for transcription of subgenomic mRNAs 
3,4
. The NC is 
tightly shielded by N protein and only opens transiently for RNA synthesis by the L polymerase 
and phosphoprotein (P) 
5,6
. Since the N protein is critical for VSV capsid and viral replication, it 
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is an ideal target for host immune system. However, whether and how the N protein is targeted by 
host innate or intrinsic immunity is unknown. Filling this knowledge gap will not only deepen our 
understanding of host defense to VSV but also pave an avenue for the development of 
therapeutics for VSV infectious disease. 
 
The tripartite motif (TRIM) proteins are a group of ubiquitin E3 ligases which play critical roles 
in innate immune signaling as well as intrinsic immunity. The ubiquitin E3 ligase activity is 
conferred by the conserved N-terminal RBCC motif comprising three domains, RING, B box, and 
coiled-coil. TRIM proteins have variable C-terminal domains that determine the interaction 
between the target proteins and TRIM proteins. It is well known that TRIM proteins mediate host 
innate immune activation and promote the induction of antiviral cytokines and chemokines, such 
as type I interferon (IFN). For instance, TRIM25 ubiquitinates the cytosolic RNA sensor, RIG-I, 
which is critical for subsequent RIG-I oligomerization and activation 
7,8
. TRIM5 interacts with 
HIV capsid and activates NF-кB signaling 
9
. Recent studies found that TRIM proteins are also 
intrinsic immune factors, which limit virus infection by directly targeting viral proteins 
10
. For 
example, TRIM32 ubiquitinates the polymerase basic 1 (PB1) of influenza A virus, which leads 




Several TRIM proteins, including TRIM41, participate in both innate immunity and intrinsic 
immunity. First, TRIM41 regulates NOD2 and cGAS innate immune signaling pathways. 
TRIM41 interacts with NOD2, but the underlying mechanism by which TRIM41 regulates NOD2 
signaling is not clear 
12
. TRIM41 also mediates monoubiquitination of the cytosolic DNA sensor 
cGAS, thereby promoting type I IFN production 
13
. Secondly, TRIM41 is an intrinsic immunity 
factor that inhibits viral infection. Our recent study discovered that TRIM41 restricts influenza by 
polyubiquitination and degradation of viral nucleoprotein 
14
. Recently, a screening of TRIM 
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proteins found that TRIM41 and other seven TRIM proteins inhibited hepatitis B virus (HBV) 
transcription 
15
. However, whether TRIM41 inhibits other viruses, such as VSV, is unknown. 
 
In this study, we demonstrate that TRIM41 inhibited VSV infection by both gain- and loss-of-
function studies. Co-Immunoprecipitation found that TRIM41 interacted with the N protein of 
VSV (VSV-N). Furthermore, TRIM41 ubiquitinated VSV-N in cells and in vitro, which led to 
proteasomal degradation of VSV-N, thus limiting VSV replication. Overall, our study establishes 
TRIM41 as a new intrinsic immune host factor against VSV. 
 
MATERIALS AND METHODS  
Cells and viruses. HEK293 cells (ATCC, # CRL-1573) and Vero cells (ATCC, # CCL-81) were 
maintained in Dulbecco’s Modified Eagle Medium (Life Technologies) containing antibiotics 
(Life Technologies) and 10% fetal bovine serum (Life Technologies). A549 cells (ATCC, # CCL-
185) were cultured in RPMI Medium 1640 (Life Technologies) plus 10% fetal bovine serum and 
1X MEM Non-Essential Amino Acids Solution (Life Technologies).  
 
VSV Indiana strain was purchased from ATCC (VR-1238). The VSV carrying a luciferase gene 
(VSV-Luc) and the VSV expressing a GFP gene (VSV-GFP) were a kind gift from Dr. Sean 
Whelan (Harvard Medical School, MA). Viral titration was performed as described in a previous 
study 
16
. Briefly, Vero cells were infected with a serial diluted VSV. After 45 min, media was 
removed and replaced by the DMEM plus 10% FBS and 1% agarose. After 48 h, cells were fixed 
using the methanol–acetic acid (3:1) fixative and stained using a Coomassie blue solution. 
 
Constructs and Reagents. TRIM41-HA was a generous gift from Dr. Adolfo Garcia-Sastre 
(Mount Sinai School of Medicine, NY) 
17
. TRIM41 was cloned into pCMV-3Tag-8 (Stratagene) 
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to generate TRIM41-FLAG. Deletion mutants of TRIM41-FLAG were constructed using a Q5
®
 
Site-Directed Mutagenesis Kit (New England Biolabs). VSV-N was cloned into pCMV-3Tag-8 
(Stratagene) and pCMV-3Tag-8-HA to generate FLAG-tagged and HA-tagged VSV-N, 
respectively. 
 
Anti-β-actin (Abcam, # ab8227), anti-FLAG (Sigma, # F3165), anti-ubiquitin (Santa Cruz 
Biotechnology, # sc-8017), anti-TRIM41 (Aviva Systems Biology, # ARP34763_P050), anti-HA 
epitope (Cell Signaling Technology, # 3724), anti-VSV (Imanis Life Sciences, # REA005), anti-
VSV-N (KeraFAST, # EB0009). Goat anti-Mouse IgG-HRP (Santa Cruz Biotechnology, # sc-
2055), Goat anti-Rabbit IgG-HRP (Santa Cruz Biotechnology, # sc-2030), Alexa Fluor 594 Goat 
Anti-Mouse IgG (H+L) (Life Technologies, # A11005), Alexa Fluor 488 Goat Anti-Rabbit IgG 
(H+L) (Life Technologies, # A11034). 
Sample preparation, Western blotting and immunoprecipitation. Approximately 1 X 10
6
 
cells were lysed in 500 µl of tandem affinity purification (TAP) lysis buffer [50 mM Tris-HCl 
(pH 7.5), 10 mM MgCl2, 100 mM NaCl, 0.5% Nonidet P40, 10% glycerol, Complete EDTA-free 
protease inhibitor cocktail tablets (Roche)] for 30 min at 4⁰C. The lysates were then centrifuged 
for 30 min at 15,000 x g. Supernatants were collected and mixed with 1X Lane Marker Reducing 
Sample Buffer (Thermo Fisher Scientific). Western blotting and immunoprecipitation were 




Immunofluorescence assay. Cells were cultured in the Lab-Tek II CC2 Chamber Slide System 
4-well (Thermo Fisher Scientific). After the indicated treatment, the cells were fixed and 
permeabilized in cold methanol for 10 min at -20 ⁰C. Then, the slides were washed with 1 X 
DPBS for 10 min and blocked with Odyssey Blocking Buffer (LI-COR Biosciences) for 1 h. The 
slides were incubated in Odyssey Blocking Buffer with 1:100 diluted primary antibodies at 4 ⁰C 
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for 12 h. Images were captured and analyzed using an iRiS
TM
 Digital Cell Imaging System 
(Logos Biosystems). 
 
Plasmid transfection. Transfections using Lipofectamine 2000 or Lipofectamine 3000 
Transfection Reagent (Life Technologies) were performed according to the manufacturer’s 
protocol. For co-IP experiments, a total of 2.5 µg of plasmids was transfected into approximately 
1.2 x 10
6
 cells. For other experiments, a total of 0.5 µg of plasmids was transfected into 
approximately 0.2 x 10
6
 cells.   
 
RNA interference. RNAi target sequences (sense strand): TRIM41 siRNA #2: 
AAGGCGTGCTGTGGAAATAAA; TRIM41 siRNA #3: TTCAATAGGTGTGAAGAGGTA. 
siGENOME Non-Targeting Control siRNA (Dharmacon, # D-001210-02-05) was used as the 
control siRNA. 5 pmol of siRNA duplexes were transfected into A549 cells using Lipofectamine 
RNAiMAX Transfection Reagent (Life Technologies) according to the manufacturer’s protocol. 
 
CRISPR/Cas9. The single guide RNA (sgRNA) sequence targeting human TRIM41 is: 
GTAGTCTTCATCCCGCATGG. The sgRNA was cloned into lentiCRISPR v2 
19
 (Addgene).  
0.5 µg of lentiviral construct was transfected into HEK293 cells using Lipofectamine 2000. Cells 
were selected with 10 µg/ml puromycin for 14 days. Single clones were expanded for knockout 
confirmation by Western blotting and DNA sequencing.  
 
In vitro ubiquitination. In vitro ubiquitination assay was performed according to the 
manufacturer’s manual (Boston Biochem). Ubiquitin, E1, UBCH5A (Boston Biochem), VSV-N-
FLAG, and TRIM41-HA or Del-RING-HA bound to the anti-HA resin (Sigma) were incubated at 
30°C in the ubiquitin assay reaction buffer (Boston Biochem) for 2 h. The anti-HA resin was 
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washed with 1 M urea for 15 min to exclude potential binding of unanchored polyubiquitin. Then 
the resin was incubated with 45 μL of 0.5 mg/ml HA peptide to elute VSV-N protein. The elutes 
were subsequently analyzed by SDS-PAGE followed by Western blotting. 
 
Statistical analysis. The sample size was sufficient for data analysis using paired two-tailed 
Student’s t-test. For all statistical analysis, differences were considered to be statistically 

















 TRIM41 restricts VSV infection.  
To examine the effect of TRIM41 on VSV infection, we first transfected FLAG-tagged TRIM41 
into HEK293 cells. After 48 h, cells were infected with a VSV reporter virus carrying a luciferase 
gene in the viral genome (VSV-Luc). As shown in Figure 1A, the ectopic expression of TRIM41 
inhibited VSV replication activity. 
                       
Figure 37: Effect of TRIM41 overexpression on VSV infection- Reporter Assay. HEK293 
cells transfected with TRIM41-FLAG or pCMV-3Tag-8 vector were infected with 0.1 MOI of 
VSV-Luc for 12 h. Relative luciferase activities were examined. Data represent means ± s.d. of 
three independent experiments. The P value was calculated (two-tailed Student’s t-test) by 
comparison with the vector control. An asterisk indicates P < 0.05. 
100 
 
To corroborate this finding, we further examined the effect of TRIM41 on the infection of VSV-
GFP virus that expresses a GFP protein. TRIM41 or empty vector was transfected in HEK293 
cells followed by the infection of VSV-GFP for 12 h. TRIM41 also limited VSV-GFP infection 
in HEK293 cells, indicated by the decreased GFP positive cells. 
 
 
Figure 38: Effect of TRIM41 overexpression on VSV infection- Fluorescence Assay. 
HEK293 cells were transfected with pCMV-3Tag-8 vector or TRIM41-FLAG for 24 h, then 
infected with 1 MOI of VSV-GFP for 12 h. The percentage of GFP-positive cells is summarized 




Next, we examined the effect of TRIM41 overexpression on viral protein expression. HEK293 
cells were transfected with vector or TRIM41, then were infected with different multiplicity of 
infections (MOIs) of VSV. Consistently, Western blot analysis showed that TRIM41 reduced 
VSV protein expression. 
   
 
Figure 39: Effect of TRIM41 overexpression on VSV protein expressions. HEK293 cells were 
transfected with pCMV-3Tag-8 vector or TRIM41-FLAG for 24 h, then infected with different 






Lastly, TCID50 assay was performed to determine the effect of TRIM41 overexpression on the 
production of infectious VSV particles. Overexpression of TRIM41 reduced VSV viral titers 
significantly at the time course of 6 h to 48 h. 
               
Figure 40:  Effect of TRIM41 overexpression on VSV titers.  HEK293 cells were transfected 
with pCMV-3Tag-8 vector or TRIM41-FLAG. After 24 h, cells were infected with 0.001 MOI of 
VSV. After the designated hour post infection (h.p.i.), virus titers were determined by TCID50 in 
Vero cells. All experiments were biologically repeated three times. An asterisk indicates P < 
0.05. 
 




TRIM41 deficiency increases host susceptibility to VSV 
To corroborate the gain-of-function of TRIM41, we further examined the effect of TRIM41 
depletion on VSV infection. We first depleted TRIM41 using a small interfering RNA (siRNA). 
Two validated siRNA duplexes against TRIM41 (Patil et al., 2018) were individually transfected 
into A549 lung epithelial cells. After 48 h, cells were infected with VSV-Luc for 12 h. 
Knockdown of TRIM41 increased VSV infection activity in A549 cells. 
                                        
Figure 41: Effect of TRIM41 knockdown on VSV infectious activity. A549 cells were 
transfected with 5 pmol of the control siRNA or the indicated siRNA duplex against TRIM41. 
After 48 h, the cells were infected at an MOI of 0.1 with VSV-Luc for 12 h. Relative luciferase 
activities were examined. All experiments were biologically repeated three times. Data represent 
means ± standard deviations of three independent experiments. The P value was calculated (two-
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tailed Student's t test) by comparison of results with those of the siRNA control in each cell group 
(* P < 0.05). 
Secondly, wild type and the TRIM41 knockout HEK293 cells used in our previous study (Patil et 
al., 2018) were infected with different doses of VSV-Luc for 12 h. Reporter assays demonstrated 
the increased viral infection activity in TRIM41 knockout cells. 
 
                      
Figure 42: Effect of TRIM41 knockout on VSV infectious activity. Wild type (WT) HEK293 
and TRIM41 knockout (KO) cells were infected with the indicated MOIs of VSV-Luc for 12 h. 
Relative luciferase activities were examined. All experiments were biologically repeated three 
times. An asterisk indicates P < 0.05. 
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Thirdly, we examined the infection of VSV-GFP in wild type and TRIM41 knockout HEK293 
cells. Knockout of TRIM41 resulted in an increase of the number of GFP positive cells. 
Figure 43: Effect of TRIM41 knockout on VSV – Fluorescence assay. Wild type and TRIM41 
knockout cells were infected with 0.1 MOI of VSV-GFP for 12 h. The percentage of GFP-
positive cells is summarized in the right graph. An asterisk indicates P < 0.05. 
 
Fourthly, we examined the effect of TRIM41 deficiency on viral protein expression. TRIM41 
wild type and knockout cells were infected with different doses of VSV for 12 h. As shown in 






Figure 44: Effect of TRIM41 knockout on VSV protein expression. Wild type and TRIM41 
knockout cells were infected with different MOIs of VSV for 12 h. Cell lysates were blotted using 








Lastly, viral titers were determined by TCID50 assay in TRIM41 wild type vs. knockout cells. 
VSV viral titers increased about 10-fold in knockout cells compared to wild type cells (Figure 
45), suggesting depletion of TRIM41 increases host susceptibility to VSV infection. 
 
                
 
Figure 45: Effect of TRIM41 knockout on VSV titers. Wild type and TRIM41 knockout cells 
were infected with 0.001 MOI of VSV. After the designated hour post infection, virus titers were 
determined by TCID50 assay in Vero cells. All experiments were biologically repeated three 





TRIM41 interacts with the nucleoprotein of VSV 
We previously reported that TRIM41 interacted with influenza viral protein to limit viral 
infection (Patil et al., 2018). Therefore, it is plausible that TRIM41 also interacts with VSV 
protein(s) to inhibit viral infection. In this regard, FLAG-tagged G, P, or N of VSV was co-
transfected with HA-tagged TRIM41 into HEK293 cells. Co-immunoprecipitation (co-IP) 
revealed the specific interaction between TRIM41 and the N protein of VSV (VSV-N). 
                                                   
Figure 46: Interaction of TRIM41 with VSV protein. TRIM41-HA was co-transfected with 
FLAG-tagged phosphoprotein (P), glycoprotein (G) or nucleoprotein (N) of VSV into HEK293 
cells. Cells were treated with Cell 
lysates were immunoprecipitated with the anti-FLAG antibody, and then blotted as indicated. 
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Next, we examined the subcellular localization of TRIM41 and VSV-N by immunofluorescence 
assay. FLAG-tagged VSV-N and HA-tagged TRIM41 were transfected alone or together into 
A549 cells. The immunofluorescence assays showed that TRIM41 expressed in the cytoplasm 
and the nucleus while VSV-N only expressed in the cytoplasm. 
 
 
Figure 47: TRIM41-VSV N co-localization. A549 cells were transfected with HA-tagged 
TRIM41 (TRIM41-HA) and FLAG-tagged VSV-N (VSV-N-FLAG). Cells were treated with 1 






We further examined the co-localization of endogenous TRIM41 and VSV-N during viral 
infection. A549 cells were cultured in a chamber slide and infected with 1 MOI of VSV for 24 h. 
Consistent with the ectopic expressing TRIM41, the endogenous TRIM41 was expressed in the 
cytoplasm and the nucleus. VSV-N only expressed in the cytoplasm and co-localized with 




Figure 48: VSV localization. A549 cells were mock infected or infected with VSV. Cells were 
treated with 1 μM MG132 to prevent VSV-N from degradation. After 24 h, cells were fixed with 
cold methanol and incubated with anti-VSV-N and anti-TRIM41 antibodies. Red: VSV-N; Green: 






To identify the domain of TRIM41 essential for the interaction with VSV-N, full-length TRIM41 
or domain deletion mutants from previous study were co-transfected with VSV-N into HEK293 
cells. Co-IP showed that the B-box deletion and the coiled-coil deletion mutant interacted with 
VSV-N, indicating both domains are not essential for the interaction (Fig. 49). On the contrary, 
deletion of either the RING or the SPRY domain impaired the interaction, suggesting that both 
SPRY and RING domains are required for the interaction between TRIM41 and VSV-N.  
                             
Figure 49: TRIM41 mutant- VSV nucleoprotein interaction. HA-tagged VSV-N (VSV-N-
HA) was co-transfected with the indicated FLAG-tagged TRIM41 or indicated mutants into 
HEK293 cells. Cell lysates were immunoprecipitated with anti-FLAG antibody and blotted with 
the indicated antibodies. 
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SPRY and RING domains are required for TRIM41 antiviral function 
Since the SPRY and RING domains interact with VSV-N, we examined the effect of SPRY 
deletion mutant (Del-SPRY) and RING deletion mutant (Del-RING) on VSV infection. TRIM41, 
Del-SPRY or the Del-RING was transfected into HEK293 cells, followed by infection with 
different MOIs of VSV-Luc for 12 h. Luciferase reporter assay showed that neither Del-SPRY 
nor Del-RING inhibited VSV infection (Figs. 50-51). 
                       
Figure 50: Effect of SPRY deletion on anti-VSV action of TRIM41.  HEK293 cells were 
transfected with FLAG-tagged TRIM41 or the SPRY deletion mutant (Del-SPRY). After 24 h, 
cells were infected with designated MOIs of VSV for 12 h. Relative luciferase activities were 
examined. Data represent means ± s.d. of three independent experiments. The P value was 
calculated by two-tailed Student’s t-test. An asterisk indicates P < 0.05. 
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Figure 51: Effect of RING deletion on anti-VSV action of TRIM41. HEK293 cells were 
transfected with FLAG-tagged TRIM41 or the RING deletion mutant (Del-RING). After 24 h, 
cells were infected with designated MOIs of VSV for 12 h. Relative luciferase activities were 
examined. Data represent means ± s.d. of three independent experiments. The P value was 







We further reconstituted full-length TRIM41 or the Del-RING in TRIM41 knockout cells by 
transfection. After 48 h, cells were infected with VSV-GFP. As shown in Figure 4C, full-length 
TRIM41, but not the Del-RING, restored antiviral activity against VSV in the knockout cells. 
                               
Figure 52: Effect of RING deletion on anti-VSV action of TRIM41in knockout. TRIM41 
knockout HEK293 cells were transfected with pCMV-3Tag-8 vector, TRIM41-FLAG or the Del-
RING for 24 h, then infected with 0.1 MOI of VSV-GFP for 12 h. The percentage of GFP-




Lastly, we examined viral titers in TRIM41 knockout cells reconstituted with full-length TRIM41 
vs. the Del-RING. In line with the reporter assays, the Del-RING failed to suppress VSV 
infection evidenced by TCID50 assay.  
 
            
Figure 53: Effect of RING deletion of TRIM41 on VSV titers. HEK293 knockout cells were 
transfected with wild type TRIM41 or the Del-RING mutant. After 24 h, cells were infected with 
0.001 MOI of VSV. After the designated hour post infection, virus titers were determined by 
TCID50 assay in Vero cells. All experiments were biologically repeated three times.  
 




TRIM41 mediates ubiquitination and degradation of VSV-N 
TRIM41 has been shown to promote cytosolic DNA-induced type I IFN production (Liu et al., 
2018). Whether TRIM41 regulates type I IFN production induced by the cytosolic RNA, such as 
VSV RNA, is unknown. Thus, we transfected vector or TRIM41 together with NF-
interferon-stimulated response element (ISRE) reporter into HEK293T cells. We used HEK293T 
cells because the HEK293T cells have an intact RNA sensing pathway, but the DNA sensing 
pathway is defective. As shown in Figure 54, the deficiency of TRIM41 has little effect on the 
reporter activity of either NF-B or ISRE, suggesting TRIM41 is dispensable for cytosolic RNA-
mediated innate immunity.  
                                
Figure 54: Effect of TRIM41 on innate immunity. One hundred ng of vector or FLAG-tagged 
FIP200 was transfected with 50 ng of pRL-SV40 (Renilla luciferase as an internal control), 
together with 100 ng of pISRE-Luc or NF-кB-Luc into HKE293 cells. After 48 h, cells were 
collected and the ratio of firefly luciferase to Renilla luciferase was calculated to determine the 
relative reporter activity. All experiments were repeated three times. 
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Although RING mediates the interaction with VSV-N, the RING domain is well known to confer 
the E3 ubiquitin ligase activity of TRIM proteins. Therefore, the requirement of RING also 
suggests that TRIM41 might inhibit VSV infection through ubiquitination of VSV-N. To examine 
whether TRIM41 can conjugate ubiquitin molecules onto VSV-N, we first performed an in vitro 
ubiquitination assay. As shown in Figure 55, TRIM41, but not the Del-RING, conjugated the 
ubiquitin molecules onto VSV-N. 
                             
Figure 55: In vitro ubiquitination of VSV-N by TRIM41. FLAG-tagged VSV-N, HA-tagged 
TRIM41 and the Del-RING mutant, plus E1, E2 (UBCH5A), ATP and ubiquitin were added as 
indicated and incubated at 30°C for 2 h. Samples were blotted with the indicated antibodies. 
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Consistently, overexpression of wild type TRIM41, but not the Del-RING mutant, induced the 
ubiquitination of VSV-N in HEK293 cells. 
                                            
Figure 56: TRIM41 mediated VSV N ubiquitination. FLAG-tagged VSV-N was co-transfected 
with vector, TRIM41-HA or the HA-tagged Del-RING mutant together with Myc-tagged 
ubiquitin (Ub- -N 
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from degradation. Cell lysates were immunoprecipitated with anti-FLAG antibody and blotted 
with the indicated antibodies. 
Next, we examined VSV-N ubiquitination in TRIM41 knockout cells. VSV-N was transfected 
with HA-tagged ubiquitin into wild type and TRIM41 knockout HEK293 cells. Knockout of 
TRIM41 dramatically reduced the levels of polyubiquitin chain conjugated onto VSV-N. 
                       
Figure 57: Effect of TRIM41 knockout on VSV N ubiquitination. Wild type and TRIM41 
knockout HEK293 cells were transfected with FLAG-tagged VSV-N and HA-tagged ubiquitin 
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(Ub-HA). Cell lysates were immunoprecipitated with anti-FLAG antibody and blotted with the 
indicated antibodies. 
These experiments suggest that TRIM41 mediates polyubiquitination of VSV-N. 
Polyubiquitination often leads to proteasomal degradation of the targeted protein. Thus, we 
further examined whether TRIM41 mediates VSV-N protein degradation.  VSV-N was co-
transfected with TRIM41 or the Del-RING into HEK293 cells. Overexpression of full-length 
TRIM41 reduced the VSV-N expression; however, the Del-RING had a marginal effect on the 
expression of VSV-N protein. 
                        
Figure 58: RING dependent TRIM41 mediated VSV N degradation. FLAG-tagged VSV-N 
(VSV-N-FLAG) was co-transfected with HA-tagged TRIM41 or the Del-RING mutant into 




Furthermore, we treated cells with the protease inhibitor MG132 to determine whether TRIM41-
mediated protein degradation of VSV-N is proteasome-dependent. HEK293 cells were 
transfected with VSV-N along with TRIM41 or vector. After 48 h, cells were treated with the 
protease inhibitor MG132 for 6 h. Western blot analysis found that MG132 treatment blocked 
TRIM41-mediated VSV-N degradation. 
                   
Figure 59: TRIM41 mediated VSV N degradation. HA-tagged VSV-N (VSV-N-HA) was co-
transfected with vector or TRIM41-FLAG into HEK293 cells. After 24 h, cells were treated with 
lysates were then blotted with the indicated antibodies. 
 
In all, the combined data indicate that TRIM41 mediates ubiquitination of VSV-N, which leads to 




Innate immunity and intrinsic immunity are the frontlines of host defense to the invading viruses. 
Innate immunity comprises of various signaling cascades leading to the expression of type I IFN 
and many other antiviral genes. These innate immune signaling pathways are triggered by the 
products and/or by-products of microbes, which are usually foreign to the host. The Toll-like 
receptor 7 (TLR7) and RIG-I are the sensors that recognize the 5`-ppp-RNA of VSV in the 
endosome and the cytoplasm, respectively 
20,21
. Upon the engagement with viral RNA, TLR7 and 
RIG-I activate signaling cascades, which lead to the induction of type I IFN expression 
22-26
. 
Unlike innate immunity factors, the intrinsic immunity factors are a group of constitutively 
expressed host factors. The “pre-existed” expression of these host factors guarantees a more rapid 
response and a direct inhibition of viral infection 
10,27
. For example, the cytidine deaminase, 
apolipoprotein editing complex 3 G (APOBEC3G), introduces transversion mutations into the 
HIV genome, thereby impeding HIV infection 
28
. It is well established for how innate immunity 
responds to VSV infection; however, the intrinsic immune response to VSV is still elusive. Here, 
we report that TRIM41 interacts with the N protein of VSV and subsequently targets it for 
ubiquitination and proteasomal degradation. Our previous study showed that TRIM41 is 
constitutively expressed 
14
. Thus, TRIM41 is a new intrinsic immune factor to VSV.  
 
TRIM41 belongs to the TRIM family that consists of more than 70 members. Recently, many 
TRIM proteins are identified as intrinsic immune factors that curb viral infection through directly 
targeting viral proteins. For instance, TRIM32 restricts influenza A virus by targeting PB1 protein 
for ubiquitination and degradation 
11
. TRIM22 and TRIM14 restrict hepatitis C virus by targeting 
NS5α for ubiquitination and degradation 
29,30
. TRIM52 interacts with the nonstructural protein 2A 
of Japanese encephalitis virus and mediates NS2A ubiquitination and protein degradation 
31
. Our 
study showed TRIM41 inhibited VSV infection by mediating proteasomal degradation of the N 
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protein. It should be noted that another TRIM protein, PML (also known as TRIM19), has been 
implied a role in VSV infection. Overexpression of PML in CHO cells increased the resistance to 
infection of VSV 
32
. Furthermore, PML deficiency increases mice susceptibility to VSV infection 
33
. A recent mechanistic study showed that PML enhances IFN synthesis by regulating the 
cellular distribution of Pin1 (peptidyl-prolyl cis/trans isomerase). The interaction of PML with 
endogenous Pin1 prevents the degradation of activated IRF3, thereby potentiating IRF3-




Our previous study demonstrates that TRIM41 directly restricts influenza A virus by 
ubiquitination and degradation of nucleoprotein 
14
. TRIM41 also inhibits HBV activity, which is 
dependent on the ubiquitin E3 ligase activity and the C-terminal domain of TRIM41 
15
. Thus, 
TRIM41 has emerged as a broad-spectrum antiviral factor. Like TRIM41, several other TRIM 
proteins are reported to have a broad-spectrum antiviral activity. PML also inhibits herpesvirus 
and adeno-associated virus 
35
. TRIM56 restricts influenza B virus, HIV, yellow fever virus, and 
dengue virus by reducing the viral RNA levels through its C-terminal tail 
36,37
. TRIM22 restricts 
encephalomyocarditis virus, influenza A virus, hepatitis B virus, and hepatitis C virus 
29,38-40
. 
However, the underlying mechanism for the broad-spectrum antiviral activity of TRIM proteins is 
unknown. To determine the broad-spectrum antiviral activity, it is important to identify the 
common mechanism. Future studies will determine whether the interacting viral proteins share a 
common motif for TRIM41 interaction.  
 
Our previous study 
14
 and this study show the endogenous TRIM41 localizes in the cytoplasm and 
the nucleus. Furthermore, ectopic expression of TRIM41 also show the cytosolic and nuclear 
localization in this study. Consistently, previous studies by other groups also reported both 
cytosolic and nuclear localization of TRIM41 
41,42
. Viral infection may change the subcellular 





However, we have not found that either VSV or influenza A virus alters cellular localization of 
TRIM41. The dual subcellular localization of TRIM41 makes it access to the substrate in the 
cytoplasm and the nucleus, thereby inhibiting cytosolic replication virus, such as VSV, and the 
nuclear replication virus, such as influenza A virus. 
 
VSV life cycle comprise of four major steps: entry, replication and transcription, virion assembly, 
and progeny release. As TRIM41 is a cytosolic and nuclear protein, it unlikely TRIM41 interferes 
with viral entry and release because these steps involve host membrane proteins. For example, 
ZMPSTE24, an endosomal protein found in our previous study, blocks the entry of VSV and 
other viruses 
43
. The N protein of VSV is critical for VSV RNA replication and transcription 
3,4
. 
As TRIM41 mediates VSV-N for protein degradation, it is plausible that TRIM41 inhibits VSV 
replication and transcription. Indeed, the VSV reporter viruses, VSV-Luc and VSV-GFP, carry a 
reporter gene whose expression is controlled by VSV polymerase. The reporter activity of these 
two VSV viruses indicates the activity of VSV transcription activity. VSV-N is also a major viral 
protein for VSV nucleocapsid, therefore, TRIM41 might interfere with the assembly of the 
nucleocapsid. Future studies will investigate this hypothesis. 
 
CONCLUSION 
We demonstrate that TRIM41 targets the N protein to inhibit VSV infection. The N protein 
covers the entire VSV genomic RNA and plays an important role in viral transcription and 
replication, which makes the N protein an ideal drug target. Thus, our study provides a foundation 
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